<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1301210414
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Segluromet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METFORMIN HYDROCHLORIDE,ERTUGLIFLOZIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000,2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        171.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MSD International GmbH (PUERTO RICO Branch)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MSD International GmbH (PUERTO RICO Branch)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Merck Sharp & Dohme B.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BD
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Segluromet is</p><p>Segluromet contains two active substances, ertugliflozin and metformin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ertugliflozin belongs to a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metformin belongs to a group of medicines called biguanides.</p><p>&nbsp;</p><p>What Segluromet is used for</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segluromet lowers blood sugar levels in adult patients (aged 18 years and older) with type 2 diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segluromet can be used instead of taking both ertugliflozin and metformin as separate tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segluromet can be used alone or with some other medicines that lower blood sugar.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You need to keep following your food and exercise plan while taking Segluromet.</p><p>&nbsp;</p><p>How Segluromet works</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ertugliflozin works by blocking the SGLT2 protein in your kidneys. This causes blood sugar to be removed in your urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metformin works by inhibiting sugar (glucose) production in the liver.</p><p>&nbsp;</p><p>What is type 2 diabetes?</p><p>Type 2 diabetes is a condition in which your body does not make enough insulin or the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems, like heart disease, kidney disease, blindness and poor circulation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Segluromet</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to ertugliflozin or metformin or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severely reduced kidney function or need dialysis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis (see &ldquo;Risk of lactic acidosis&rdquo; below) or ketoacidosis. Ketoacidosis is a condition in which substances called &lsquo;ketone bodies&rsquo; accumulate in the blood and which can lead to diabetic pre-coma. Symptoms include stomach pain, fast and deep breathing, sleepiness, or your breath developing an unusual fruity smell.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe infection or are dehydrated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently had a heart attack or have severe circulatory problems, such as &lsquo;shock&rsquo; or breathing difficulties.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you drink alcohol to excess (either regularly or from time to time).</p><p>Do not take Segluromet if any of the above apply to you. If you are not sure, talk to your doctor before taking Segluromet.</p><p>&nbsp;</p><p>Warnings and precautions</p><p><strong>&nbsp;</strong></p><p>Talk to your doctor, pharmacist, or nurse before and while taking Segluromet, if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or have had yeast infections of the vagina or penis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have ever had serious heart disease or if you have had a stroke.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have type 1 diabetes. Segluromet should not be used to treat this condition.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take other diabetes medicines; you are more likely to get low blood sugar with certain medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; might be at risk of dehydration (for example, if you are taking medicines that increase urine production [diuretics] lower blood pressure or if you are over 65 years old). Ask about ways to prevent dehydration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat, contact a doctor or the nearest hospital straight away. These symptoms could be a sign of &ldquo;diabetic ketoacidosis&rdquo; &ndash; a problem you can get with diabetes because of increased levels of &ldquo;ketone bodies&rdquo; in your urine or blood, seen in tests. The risk of developing diabetic ketoacidosis may be increased with prolonged fasting, excessive alcohol consumption, dehydration, sudden reductions in insulin dose, or a higher need of insulin due to major surgery or serious illness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had a lower limb amputation.</p><p>&nbsp;</p><p>It is important to check your feet regularly and adhere to any other advice regarding foot care and adequate hydration given by your healthcare professional. You should notify your doctor immediately if you notice any wounds or discolouration, or if you experience any tenderness or pain in your feet. Some studies indicate that taking ertugliflozin may have contributed to an increase in cases of lower limb amputation (mainly of the toe).</p><p>&nbsp;</p><p>Talk to your doctor immediately if you develop a combination of symptoms of pain, tenderness, redness, or swelling of the genitals or the area between the genitals and the anus with fever or feeling generally unwell. These symptoms could be a sign of a rare but serious or even life-threatening infection, called necrotising fasciitis of the perineum or Fournier&rsquo;s gangrene which destroys the tissue under the skin. Fournier&rsquo;s gangrene has to be treated immediately.</p><p>&nbsp;</p><p>When this medicine is used in combination with insulin or medicines that increase insulin release from the pancreas, low blood sugar (hypoglycaemia) can occur. Your doctor may reduce the dose of your insulin or other medicine.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>Risk of lactic acidosis</p><p>Segluromet may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration (see further information below), liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen (such as acute severe heart disease).</p><p>If any of the above apply to you, talk to your doctor for further instructions.</p><p>&nbsp;</p><p><strong>Stop taking Segluromet for a short time if you have a condition that may be associated with dehydration </strong>(significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. Talk to your doctor for further instructions.</p><p>&nbsp;</p><p><strong>Stop taking Segluromet and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis</strong>, as this condition may lead to coma.</p><p>Symptoms of lactic acidosis include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach ache (abdominal pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a general feeling of not being well with severe tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced body temperature and heartbeat</p><p>Lactic acidosis is a medical emergency and must be treated in a hospital.</p><p>&nbsp;</p><p>If you need to have major surgery you must stop taking Segluromet during and for some time after the procedure. Your doctor will decide when you must stop and when to restart your treatment with Segluromet.</p><p>&nbsp;</p><p>During treatment with Segluromet, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or if you have worsening kidney function.</p><p>&nbsp;</p><p>Urine glucose</p><p>Because of how Segluromet works, your urine will test positive for sugar (glucose) while you are on this medicine.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Children and adolescents below 18 years should not take this medicine. It is not known if this medicine is safe and effective when used in children and adolescents under 18 years of age.</p><p>&nbsp;</p><p>Other medicines and Segluromet</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dose of Segluromet. In particular, tell your doctor:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines which increase urine production (diuretics).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking other medicines that lower the sugar in your blood, such as insulin or medicines that increase insulin release from the pancreas.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as ibuprofen and celecoxib).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II receptor antagonists).</p><p>If any of the above apply to you (or you are not sure), tell your doctor.</p><p>&nbsp;</p><p>If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example, in the context of an X-ray or scan, you must stop taking Segluromet before or at the time of the injection. Your doctor will decide when you must stop and when to restart your treatment with Segluromet.</p><p>&nbsp;</p><p>Segluromet with alcohol</p><p>Avoid excessive alcohol intake while taking Segluromet since this may increase the risk of lactic acidosis (see section &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>It is not known if Segluromet can harm your unborn baby. If you are pregnant, talk with your doctor about the best way to control your blood sugar while you are pregnant. You should not use Segluromet if you are pregnant.</p><p>&nbsp;</p><p>It is not known if Segluromet passes into breast milk. Talk with your doctor about the best way to feed your baby if you take this medicine. You should not use Segluromet if you are breast-feeding.</p><p>&nbsp;</p><p>Driving and using machines</p><p>This medicine has no or negligible influence on the ability to drive and use machines. Taking this medicine in combination with insulin or medicines that increase insulin release from the pancreas can cause blood sugar levels to drop too low (hypoglycaemia), which may cause symptoms such as shaking, sweating and change in vision, and may affect your ability to drive and use machines. Do not drive or use any tools or machines if you feel dizzy while taking Segluromet.</p><p>&nbsp;</p><p>Segluromet contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>How much to take</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose of Segluromet is one tablet twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose of Segluromet that you take will depend on your condition and the amount of ertugliflozin and metformin needed to control your blood sugar.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will prescribe the right dose for you. Do not change your dose unless your doctor has told you to.</p><p>&nbsp;</p><p>Taking this medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet; if you have difficulties in swallowing the tablet can be broken or crushed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take one tablet twice daily. Try to take it at the same time each day; this will help you remember to take it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is best to take your tablet with a meal. This will lower your chance of having an upset stomach.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You need to keep following your food and exercise plan while taking Segluromet.</p><p>&nbsp;</p><p>If you take more Segluromet than you should</p><p>If you take too much Segluromet, talk to a doctor or pharmacist straight away.</p><p>&nbsp;</p><p>If you forget to take Segluromet</p><p>If you forget a dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose and go back to your regular schedule.</p><p>&nbsp;</p><p>Do not take a double dose (two doses at the same time) to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you stop taking Segluromet</p><p>Do not stop taking this medicine without talking to your doctor. Your blood sugar levels may increase if you stop the medicine.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Contact a doctor or the nearest hospital straight away if you have any of the following serious side effects:</p><p><strong>&nbsp;</strong></p><p><strong>Lactic acidosis (very rare, may affect up to </strong><strong>1 in 10,000 people)</strong></p><p>Segluromet may cause a very rare, but very serious side effect called lactic acidosis (see section &ldquo;Warnings and precautions&rdquo;). If this happens, you must stop taking Segluromet and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma.</p><p>&nbsp;</p><p>Diabetic ketoacidosis (rare, may affect up to 1 in 1,000 people)</p><p>These are the signs of diabetic ketoacidosis (see also section &ldquo;Warnings and precautions&rdquo;):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of &ldquo;ketone bodies&rdquo; in your urine or blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick or being sick</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive thirst</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast and deep breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual sleepiness or tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat</p><p>This may occur regardless of blood glucose level. Your doctor may decide to temporarily or permanently stop your treatment with Segluromet.</p><p>&nbsp;</p><p>If you notice any of the side effects above, contact a doctor or the nearest hospital straight away.</p><p>&nbsp;</p><p>Contact your doctor as soon as possible if you notice the following side effects:</p><p><strong>&nbsp;</strong></p><p><strong>Dehydration (losing too much water from your body; common, may affect up to </strong><strong>1 in 10 people)</strong></p><p>Symptoms of dehydration include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy, light-headed, or weak, especially when you stand up</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>&nbsp;</p><p>You may be more likely to get dehydrated if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take medicines that increase your urine production (diuretics) or lower blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are 65 years or older</p><p>&nbsp;</p><p>Low blood sugar (hypoglycaemia; common)</p><p>Your doctor will tell you how to treat low blood sugar and what to do if you have any of the symptoms or signs below. The doctor may lower the dose of your insulin or other diabetes medicine.</p><p>Signs and symptoms of low blood sugar may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritability</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hunger</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling jittery</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart beat</p><p>If you notice any of the side effects above, contact your doctor as soon as possible.</p><p>Other side effects include: Very common</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal yeast infection (thrush)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach ache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&nbsp;</p><p>Common</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yeast infections of the penis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in urination, including urgent need to urinate more often, in larger amounts, or at night</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thirst</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show changes in the amount of urea in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show changes in the amount of total and bad cholesterol (called LDL - a type of fat in your blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show changes in the amount of red blood cells in your blood (called haemoglobin)</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show changes related to kidney function (such as &lsquo;creatinine&rsquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful urination</p><p>&nbsp;</p><p>Very rare</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased vitamin B12&nbsp;levels. This may cause anaemia (low levels of red blood cells).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver function test disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatitis (a liver problem)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the National Pharmacovigilance and Drug Safety Centre (NPC). SFDA. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP.</p><p>Store below 30&deg;C.&nbsp; Store in the original package</p><p>&nbsp;</p><p>Do not use this medicine if the packaging is damaged or shows signs of tampering.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are ertugliflozin and metformin.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each Segluromet 2.5 mg/1,000 mg film-coated tablet contains 2.5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 1,000 mg of metformin hydrochloride.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each Segluromet 7.5 mg/1,000 mg film-coated tablet contains 7.5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 1,000 mg of metformin hydrochloride.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet core: povidone (E1201), microcrystalline cellulose (E460), crospovidone (E1202), sodium lauryl sulfate (E487), magnesium stearate (E470b).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Film coating:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Segluromet 2.5 mg/1,000 mg tablets and Segluromet 7.5 mg/1,000 mg tablets: hypromellose (E464), hydroxypropyl cellulose (E463), titanium dioxide (E171), iron oxide red (E172), carnauba wax (E903).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Segluromet 2.5 mg/1,000 mg film-coated tablets (tablets) are pink, 19.1 x 10.6 mm oval, film-coated tablets debossed with “2.5/1000” on one side and plain on the other side.
•	Segluromet 7.5 mg/1,000 mg film-coated tablets (tablets) are red, 19.1 x 10.6 mm oval, film-coated tablets debossed with “7.5/1000” on one side and plain on the other side.

Segluromet is available in Alu/PVC/PA/Alu blisters. The pack sizes are 14, 28, 56, 60, 168, and 180 film-coated tablets in non-perforated blisters, multipack containing 196 (4 packs of 49) film
coated tablets in non-perforated blisters and 30x1 film-coated tablets in perforated unit dose blisters. 

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder:</p><p>Merck Sharp &amp; Dohme B.V.</p><p>Waarderweg</p><p>2031 BN Haarlem</p><p>The Netherlands</p><p>&nbsp;</p><p>Manufacturer:</p><p>MSD International GmbH (Puerto Rico Branch) L.L.C.</p><p>State Road 183</p><p>PRIDCO Industrial Park</p><p>Las Piedras, Puerto Rico 00771 United States</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in July 2020


To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance Centre (NPC):
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa
•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions  of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.

Council of Arab Health Ministers  
 Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food & Drug Authority. 

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما </strong>سيقلورومِت<br />يحتوي سيقلورومِت على مادتين فعّالتين هما إرتوقليفلوزين/ ميتفورمين:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إرتوقليفلوزين ؛ ينتمي إلى مجموعة من الأدوية تُسمّى مثبطات الناقل المشارك للصوديوم/جلوكوز-2 (SGLT2) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ميتفورمين الذي ينتمي إلى مجموعة من الأدوية تُدعى بيقوانيد.</p><p dir="RTL"><strong>دواعي استخدام</strong> <strong>سيقلورومِت</strong></p><p dir="RTL">&bull; يقلل سيقلورومِت من مستويات السكر في الدم لدى المرضى البالغين (الذين تتراوح أعمارهم بين 18 سنة وما فوق) المصابين بمرض السكري من النوع 2.</p><p dir="RTL">&bull; يمكن استخدام سيقلورومِتب بدلًا من استخدام كلٍّ من إرتوقليفلوزين وميتفورمين كأقراص منفصلة.</p><p dir="RTL">&bull; يمكن استخدام سيقلورومِت بمفرده أو مع بعض الأدوية الأخرى التي تُخفض نسبة السكر في الدم.</p><p dir="RTL">&bull; تحتاج إلى متابعة الالتزام في خطة الغذاء والتمارين أثناء تناول سيقلورومِت.</p><p dir="RTL"><br /><strong>طريقة عمل سيقلورومِت</strong></p><p dir="RTL">&bull; يعمل إرتوقليفلوزين عن طريق تثبيط عمل بروتين SGLT2 في الكليتين، مما يؤدي إلى طرح سكّر الدم في البول.</p><p dir="RTL">&bull; يعمل ميتفورمين عن طريق تثبيط إنتاج السكر (الجلوكوز) في الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هو مرض السكري من النوع 2</strong></p><p dir="RTL">مرض السكري من النوع الثاني هو حالة مرضية يصبح فيها جسمك غير قادر على إنتاج كمية كافية من الأنسولين أو أنّ الأنسولين الذي ينتجه الجسم لا يعمل كما يجب. يمكن أن يقوم جسمك أيضًا بإنتاج الكثير من السكر. عندما يحدث هذا، يتراكم السكر (الجلوكوز) في الدم مما قد يؤدي إلى مشاكل طبية خطيرة، مثل أمراض القلب وأمراض الكلى والعمى وضعف الدورة الدموية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم </strong><strong>سيقلورومِت</strong><br />&bull; إذا كنت تعاني من حساسية تجاه إرتوقليفلوزين أو ميتفورمين أو تجاه أيّ من المكونات الأخرى لهذا&nbsp; الدواء (المذكورة في القسم 6).</p><p dir="RTL">&bull; إذا كنت تعاني من انخفاض شديد في وظائف الكلى أو كنت بحاجة لغسيل الكلى.</p><p dir="RTL">&bull; إذا كان لديك مرض السكري غير منضبط مع، على سبيل المثال، فرط سكر الدم الشديد (جلوكوز الدم المرتفع)، والغثيان، والتقيؤ، والإسهال، وفقدان الوزن السريع، والحُماض اللبني (اللاكتيكي) (انظر &quot;خطر الحُماض اللبني (اللاكتيكي) &quot; أدناه) أو الحُماض الكيتوني. الحماض الكيتوني هو حالة تتراكم فيها المواد المسماة &quot;الأجسام الكيتونية&quot; في الدم والتي يمكن أن تؤدي إلى ما قبل غيبوبة السكري. تشمل الأعراض الألم في المعدة، والتنفس السريع و العميق ، والنعاس، أو ظهور رائحة لنَفَسِك غير عادية تشبه رائحة الفواكه.</p><p dir="RTL">&bull; إذا كنت تعاني من عدوى شديدة أو من الجفاف.</p><p dir="RTL">&bull; إذا كنت قد تعرضت مؤخرا لنوبة قلبية أو لديك مشاكل شديدة في الدورة الدموية، مثل &quot;صدمة&quot; أو صعوبات في التنفس.</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل في الكبد.</p><p dir="RTL">&bull; إذا كنت تشرب الكحول بكثرة (سواء بشكل منتظم أو من وقت لآخر).</p><p dir="RTL">لا تتناول سيقلورومِت إذا كان أيّ مما ورد أعلاه ينطبق عليك. إذا لم تكن متأكدًا، استشر طبيبك قبل أن تتناول سيقلورومِت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرض قبل وأثناء استخدام سيقلورومِت إذا كنت:</p><p dir="RTL">&bull; تعاني من مشاكل في الكلى.</p><p dir="RTL">&bull; تعاني أو سبق وعانيت من عدوى فطريّة في المهبل أو القضيب.</p><p dir="RTL">&bull; سبق وأن عانيت من مرض خطير في القلب أو أُصبت بسكتة دماغية.</p><p dir="RTL">&bull; تعاني من مرض السكري من النوع 1. يجب عدم استخدام سيقلورومِت لعلاج هذه الحالة.</p><p dir="RTL">&bull; تتناول أدوية أخرى لعلاج مرض السكري: قد تكون أكثر عرضة للإصابة بانخفاض السكر في الدم عند استخدام سيقلورومِت مع بعض الأدوية الأخرى.</p><p dir="RTL">&bull; مُعرّض لخطر حدوث الجفاف (على سبيل المثال، إذا كنت تتناول أدوية تزيد من إنتاج البول [مدرات البول] أو أدوية لعلاج ضغط الدم المُرتفع أو إذا كان عمرك يزيد عن 65 عامًا). اسأل طبيبك عن طرق تجنّب حدوث الجفاف.</p><p dir="RTL">&bull; تتعرض لفقدان الوزن السريع، والشعور بالمرض أو حدوث المرض، وألم البطن، والعطش الشديد، والتنفس السريع والعميق، والارتباك، والنعاس أو التعب غير العادي، وظهور رائحة حلوة لنَفَسِك (رائحة الفاكهة)؛ أو الإحساس بطعم حلو أو معدني في فمك أو تغيّر رائحة البول أو العرَق لديك، راجع طبيبك أو &nbsp;أقرب مستشفى على الفور. قد تكون هذه الأعراض علامة على حدوث &quot;الحماض الكيتوني السكري&quot; - وهي مشكلة يمكن أن تحدث بسبب مرض السكري نتيجة زيادة مستويات &quot;الأجسام الكيتونيّة&quot; في البول أو الدم،<br />&nbsp; والتي تظهر في الفحوصات. قد يزداد خطر الإصابة بالحُماض الكيتوني السكّري مع الصيام لفترات طويلة، والإفراط في استهلاك الكحول، والجفاف، والتخفيض المفاجئ في جرعة الأنسولين، أو مع الحاجة لكميات أعلى من الأنسولين بسبب الخضوع لجراحة كبرى أو التعرّض لمرض خطير.</p><p dir="RTL">&bull; بتر في الطرف السفلي.</p><p dir="RTL">&nbsp;</p><p>Arabic translation.&nbsp;</p><p dir="RTL">من المهم فحص قدميك بانتظام والالتزام بأي نصيحة أخرى تتعلق برعاية القدم والترطيب الكافي الذي يمنحه أخصائي الرعاية الصحية. يجب عليك إخطار طبيبك على الفور إذا لاحظت أي جروح أو تغير اللون، أو إذا كنت تعاني من أي ألم في قدميك. تشير بعض الدراسات إلى أن تناول إرتوقليفلوزين قد يكون ساهم في زيادة حالات بتر الأطراف السفلية بشكل رئيسي من إصبع القدم. تحدث إلى طبيبك على الفور إذا كنت تعاني من الألم أو أو الاحمرار أو تورم الأعضاء التناسلية أو المنطقة الواقعة بين الأعضاء التناسلية والإصابة بالحمى أو الشعور بتوعك عام. يمكن أن تكون هذه الأعراض علامة على عدوى نادرة ولكنها خطيرة أو حتى مهددة للحياة، تسمى غرغرينا فورنييه التي تدمر الأنسجة تحت الجلد. غرغرينا فورنييه يجب أن تعالج على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يحدث انخفاض في نسبة السكر في الدم (نقص سكر الدم) عند استخدام هذا الدواء بالاشتراك مع الأنسولين أو الأدوية التي تُحفّز إفراز الأنسولين من البنكرياس. قد يقلل الطبيب لك جرعة الأنسولين أو أي دواء آخر تتناوله.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.<br />&nbsp;</p><p dir="RTL"><strong>خطر الحُماض اللبني (اللبني (اللاكتيكي)) </strong></p><p dir="RTL">قد يتسبب استخدام سيقلورومِت في حدوث عرض جانبي نادر جدًّا ولكنه خطير جدًّا يُسمى الحُماض اللبني (اللبني (اللاكتيكي)) ، خاصةً إذا كانت الكليتان لا تعملان لديك بشكل جيد. يزداد خطر الإصابة بالحُماض اللبني (اللبني (اللاكتيكي)) أيضًا مع الإصابة بمرض السكري غير المُنضبط، أو العدوى الخطيرة ، أو الصيام لفترات طويلة أو تناول الكحول، أو الجفاف (انظر مزيدًا من المعلومات أدناه) ، ومشاكل الكبد وأيّ حالات طبية يتعرض فيها جزء من الجسم إلى نقص في إمدادات الأكسجين ( مثل مرض القلب الحاد الشديد).</p><p dir="RTL">إذا كان أيّ من الحالات المذكورة أعلاه ينطبق عليك ، استشر طبيبك لتحصل على المزيد من التعليمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن تناول سيقلورومِت لفترة قصيرة إذا كان لديك حالة مرتبطة بحدوث الجفاف</strong> (فقدان كبير في سوائل الجسم) مثل القيء الشديد أو الإسهال أو الحمى أو التعرض للحرارة أو إذا قلّت كمية السوائل التي تشربها عن الطبيعي. تحدث إلى طبيبك لتحصل على المزيد من التعليمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن تناول سيقلورومِت وراجع الطبيب أو اذهب إلى أقرب مستشفى على الفور إذا واجهت بعض أعراض الحُماض اللبني (اللبني (اللاكتيكي)) </strong>، لأن هذا قد يؤدي إلى غيبوبة.</p><p dir="RTL">تشمل أعراض الحُماض اللبني (اللبني (اللاكتيكي)) :</p><p dir="RTL">&bull; التقيؤ</p><p dir="RTL">&bull; آلام المعدة (ألم في البطن)</p><p dir="RTL">&bull; تشنجات العضلات</p><p dir="RTL">&bull; شعور عام بالإعياء أو بالإرهاق الشديد</p><p dir="RTL">&bull; صعوبة في التنفس</p><p dir="RTL">&bull; انخفاض درجة حرارة الجسم وتباطؤ ضربات القلب</p><p dir="RTL">الحُماض اللبني (اللبني (اللاكتيكي)) هو حالة طبية طارئة ويجب علاجها في المستشفى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت بحاجة إلى إجراء عملية جراحية كبرى ، يجب عليك التوقف عن تناول سيقلورومِت أثناء وبعد العملية. سيقرر طبيبك متى يجب عليك التوقف عن استخدام سيقلورومِت ومتى عليك العودة إلى استخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتحقق طبيبك من وظيفة الكلى لديك مرة واحدة في السنة على الأقل أو أكثر إذا كنت مُسِنًا و/أو إذا كنت تعاني من تدهور وظائف الكلى أثناء العلاج بسيقلورومِت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سكّر البول </strong></p><p dir="RTL">سيُظهر فحص البول لديك نتيجة إيجابيّة لوجود السكر أثناء تناولك لهذا الدواء ، وذلك بسبب الطريقة التي يعمل بها سيقلورومِت.<strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب على الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا عدم تناول هذا الدواء. إذ من غير المعروف&nbsp; إذا كان هذا الدواء آمنًا وفعالًا عند استخدامه لدى هذه الفئة العُمريّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام أدوية أخرى مع </strong><strong>سيقلورومِت</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخرًا أو قد تتناول أيّ أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحتاج إلى إجراء المزيد من فحوصات جلوكوز الدم ووظائف الكلى بشكل متكرر ، أو قد يحتاج طبيبك إلى ضبط جرعة سيقلورومِت. على وجه الخصوص ، أخبر طبيبك إذا كنت تتناول أيّا مما يلي :</p><p dir="RTL">&bull; أدوية تزيد من إنتاج البول (مُدرّات البول).</p><p dir="RTL">&bull; أدوية أخرى تُقلل من كمية السكر في الدم ، مثل الأنسولين أو الأدوية التي تُحفّز إفراز الأنسولين من البنكرياس.</p><p dir="RTL">&bull; أدوية تُستخدم لعلاج الألم والالتهاب (NSAID و COX-2 ، مثل ايبوبروفين وسيليكوكسيب).</p><p dir="RTL">&bull; أدوية تُستخدم لعلاج ارتفاع ضغط الدم (مثبطات الإنزيم المحول للأنجيوتنسين ومضادات مستقبل الأنجيوتنسين II).</p><p dir="RTL">إذا كان أي من الحالات المذكورة أعلاه ينطبق عليك (أو لست متأكدًا)، أخبر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت بحاجة إلى تلقّي حقنة بمادة تباين تحتوي على اليود في مجرى الدم، على سبيل المثال، في سياق الأشعة السينية أو التصوير الاشعاعي، يجب عليك التوقف عن تناول سيقلورومِت قبل أو في وقت الحقن. سيقرر طبيبك متى يجب عليك التوقف والعودة إلى استخدام سيقلورومِت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سيقلورومِت مع الكحول</strong><br />تجنب الإفراط في تناول الكحول أثناء تناول سيقلورومِت لأن هذا قد يزيد من خطر حدوث الحُماض اللبني (اللبني (اللاكتيكي)) (انظر بند &quot;التحذيرات والاحتياطات&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مُرضعًا ، أو تعتقدين أنّك قد تكونين حاملًا ، أو تخططين لإنجاب طفل ، فعليك استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف إذا كان سيقلورومِت يضر بجنينك. إذا كنتِ حاملًا ، تحدثي مع طبيبك حول أفضل طريقة للتحكم في نسبة السكر في الدم أثناء الحمل. يجب عليك عدم استخدام هذا الدواء أثناء الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف إذا كان هذا الدواء يُفرز في حليب الثدي. استشيرى طبيبك حول أفضل طريقة لتغذية &nbsp;طفلك الرضيع إذا كنتِ تتناولين سيقلورومِت. يجب عليك عدم استخدام هذا الدواء إذا كنت ترضعين طفلك رضاعة طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">هذا الدواء ليس له تأثير يُذكر على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">يمكن أن يؤدي تناول هذا الدواء إلى جانب الأنسولين أو الأدوية التي تزيد من إفراز الأنسولين من البنكرياس إلى انخفاض شديد في مستويات السكر في الدم (نقص سكر الدم) ، مما قد يتسبب في أعراض مثل الارتعاش أو التعرق أو تغيرات في الرؤية وقد يؤثر على قدرتك على القيادة واستخدام الآلات. تجنّب القيادة واستخدام أي أدوات أو آلات إذا شعرت بالدُّوار أثناء تناول سيقلورومِت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سيقلورومِت يحتوي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الصوديوم</strong></p><p dir="RTL">&nbsp;يحتوي هذا الدواء على أقل من 1 مليمول صوديوم 23 ملغ لكل قرص ، أي &quot;خالي من الصوديوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء حسب ارشادات الطبيب أو الصيدلي تمامًا. استشر طبيبك أو الصيدلي إذا كنت غير متأكد.<br />&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">&bull; الجرعة الموصى بها من سيقلورومِت هي عدد حبة واحدة مرتين في اليوم.</p><p dir="RTL">&bull; تعتمد جرعة سيقلورومِت التي تتناولها على حالتك وكمية إرتوقليفلوزين وميتفورمين اللازمة للتحكم في نسبة السكر في الدم لديك.</p><p dir="RTL">&bull; سيصف لك الطبيب الجرعة المناسبة. لا تُغير الجرعة إلا إذا أخبرك الطبيب بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة تناول الدواء</strong></p><p dir="RTL">&bull; قم بابتلاع القرص كاملًا ؛ إذا كنت تواجه صعوبة في ابتلاع القرص ، فيمكنك كسره أو سحقه.</p><p dir="RTL">&bull; تناول عدد قرص واحد مرتين يوميًا. حاول أن تتناول الدواء في نفس الوقت من كلّ يوم ؛ سيساعدك ذلك على تذكر موعد الجرعة.</p><p dir="RTL">&bull; يُنصح بتناول الدواء مع الطعام لأن ذلك يُقلل من احتمال تعرّضك لاضطراب المعدة.</p><p dir="RTL">&bull; تحتاج إلى الاستمرار في اتباع خطة الغذاء والتمارين أثناء تناول سيغلورومِت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت من سيقلورومِت أكثر مما يجب </strong></p><p dir="RTL">إذا تناولت من سيقلورومِت أكثر مما يجب، تحدث إلى الطبيب أو الصيدلي على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تتناول إحدى جرعات سيقلورومِت </strong></p><p dir="RTL">إذا نسيت أن تتناول إحدى الجرعات، خذها حالما تتذكرها. ولكن، إذا كان الوقت قد حان لجرعتك التالية، فتجاوز الجرعة الفائتة وعد إلى جدولك المعتاد.</p><p dir="RTL">لا تتناول جرعة مضاعفة (جرعتان في نفس اليوم) للتعويض عن جرعة منسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول سيقلورومِت</strong><br />لا تتوقف عن تناول هذا الدواء دون استشارة طبيبك. قد تزيد مستويات السكر في الدم إذا توقفت عن تناول الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر الأدوية، يمكن أن يُسبب هذا الدواء أعراضًا جانبيّة وإن كانت لا تحدث لدى جميع من يتناوله.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>توقّف عن تناول سيقلورومِت وراجع الطبيب على الفور إذا لاحظت أي</strong><strong>ًّا</strong><strong> من الأعراض الجانبية الخطرة التالية:</strong></p><p dir="RTL"><strong>الحماض اللبني (اللبني (اللاكتيكي)) (نادر جدا، قد يؤثر على شخص واحد من بين 10،000 شخص)</strong><br />قد يتسبب استخدام سيقلورومِت في حدوث عرض جانبي نادر جدًّا ولكنه خطير جدًّا يُسمى الحُماض اللبني (اللاكتيكي) (أنظر فقرة التحذيرات والاحتياطات). إذا حدث ذلك، يجب عليك التوقف عن استخدام سيقلورومِت ومراجعة الطبيب أو الذهاب إلى أقرب مستشفى على الفور، لأن الحماض اللبني (اللاكتيكي) قد يؤدي إلى غيبوبة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحماض الكيتوني السكري (نادر، قد يؤثر على 1 من بين 1،000 شخص)</strong></p><p dir="RTL">الأعراض التالية تُمثل علامات الحماض الكيتوني السكري (انظر أيضا فقرة &quot;التحذيرات والاحتياطات&quot;):</p><p dir="RTL">&bull; زيادة مستويات &quot;الأجسام الكيتونيّة&quot; في البول أو الدم</p><p dir="RTL">&bull; فقدان الوزن السريع</p><p dir="RTL">&bull; الغثيان أو التقيؤ</p><p dir="RTL">&bull; ألم البطن</p><p dir="RTL">&bull; العطش الشديد</p><p dir="RTL">&bull; تنفس سريع وعميق</p><p dir="RTL">&bull; الارتباك</p><p dir="RTL">&bull; النعاس أو التعب غير المعتاد &nbsp;</p><p dir="RTL">&bull; رائحة حلوة لنَفَسِك (رائحة الفواكه)، وطعم حلو أو معدني في فمك أو تغيّر رائحة البول أو العرق لديك.</p><p dir="RTL">قد يحدث هذا بغض النظر عن مستوى السكر في الدم. قد يقرر طبيبك إيقاف علاجك بسيقلورومِت بشكل مؤقت أو دائم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أيًا من الأعراض الجانبية المذكورة أعلاه ، راجع الطبيب أو أقرب مستشفى على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اتصل بالطبيب في أقرب وقت ممكن إذا تعرّضت للأعراض الجانبية التالية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجفاف (فقدان كمية كبيرة من الماء من جسمك؛ شائع، قد يؤثر على 1 من بين 10 أشخاص)</strong></p><p dir="RTL">تشمل أعراض الجفاف ما يلي:</p><p dir="RTL">&bull; جفاف الفم</p><p dir="RTL">&bull; الشعور بالدوار، أو الدوخة، أو الضعف، خاصة عند الوقوف</p><p dir="RTL">&bull; الإغماء</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكون أكثر عرضة للإصابة بالجفاف إذا كنت:</p><p dir="RTL">&bull; تعاني من مشاكل في الكلى</p><p dir="RTL">&bull; تتناول الأدوية التي تزيد من إنتاج البول (مُدرّات البول) أو تلك الخافضة لضغط الدم</p><p dir="RTL">&bull; تبلغ 65 سنة من العمر أو أكثر</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انخفاض نسبة السكر في الدم (نقص سكر الدم؛ شائع)</strong></p><p dir="RTL">سيخبرك الطبيب عن كيفية علاج انخفاض سكر الدم وماذا تفعل إذا كان لديك أي من الأعراض أو العلامات أدناه. قد يقلل الطبيب من جرعة الأنسولين أو أي دواء آخر مضاد للسكري تستخدمه.</p><p dir="RTL">قد تشمل علامات وأعراض انخفاض نسبة السكر في الدم ما يلي:</p><p dir="RTL">&bull; الصداع</p><p dir="RTL">&bull; النعاس</p><p dir="RTL">&bull; الهيجان</p><p dir="RTL">&bull; الجوع</p><p dir="RTL">&bull; الدوخة</p><p dir="RTL">&bull; الارتباك</p><p dir="RTL">&bull; التعرق</p><p dir="RTL">&bull; الشعور بالتوتر الشديد</p><p dir="RTL">&bull; الشعور بالضعف</p><p dir="RTL">&bull; تسارع نبضات القلب</p><p dir="RTL">إذا لاحظت أيًا من الأعراض الجانبية المذكورة أعلاه، راجع طبيبك في أسرع وقت ممكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وتشمل الأعراض الجانبية الأخرى: </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا</strong></p><p dir="RTL">&bull; عدوى الفطريات المهبلية (القلاع)</p><p dir="RTL">&bull; الشعور بالمرض (الغثيان)</p><p dir="RTL">&bull; التقيؤ</p><p dir="RTL">&bull; إسهال</p><p dir="RTL">&bull; ألم المعدة</p><p dir="RTL">&bull; فقدان الشهية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong></p><p dir="RTL">&bull; عدوى الفطريات في القضيب</p><p dir="RTL">&bull; التغيرات في التبول، تتضمّن الحاجة المُلحّة إلى التبول المُتكرّر، بكميات أكبر، أو في الليل</p><p dir="RTL">&bull; العطش</p><p dir="RTL">&bull; الحكة المهبلية</p><p dir="RTL">&bull; تغيرات في حاسة التذوق</p><p dir="RTL">&bull; قد تُظهر فحوصات الدم تغيرات في كمية اليوريا في دمك</p><p dir="RTL">&bull; قد تُظهر فحوصات الدم تغيرات في كمية الكولسترول الكلّي والسيئ (تسمى LDL - نوع من الدهون في دمك)</p><p dir="RTL">&bull; قد تُظهر فحوصات الدم تغيرات في كمية كريات الدم الحمراء في الدم (تسمى الهيموقلوبين)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تُؤثر على شخص واحد من بين كل 100 شخص)</strong></p><p dir="RTL">&bull; قد تُظهر فحوصات الدم تغييرات متعلقة بوظائف الكلى (مثل &quot;كرياتينين&quot;)</p><p dir="RTL">&bull; ألم أثناء التبوّل</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًّا</strong></p><p dir="RTL">&bull; انخفاض مستويات فيتامين ب 12. هذا قد يسبب فقر الدم (انخفاض مستويات خلايا الدم الحمراء).</p><p dir="RTL">&bull; اضطرابات وظائف الكبد</p><p dir="RTL">&bull; التهاب الكبد (مشكلة في الكبد)</p><p dir="RTL">&bull; شرى</p><p dir="RTL">&bull; احمرار في الجلد</p><p dir="RTL">&bull; الحكة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبيّة</strong><br />إذا أُصبت بأيّ أعراض جانبية، تحدث مع طبيبك أو الصيدلي أو الممرض. يتضمن ذلك أيّ أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً &nbsp;عن &quot;طريق المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء&quot;. يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ عن الأعراض الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيفية تخزين سيقلورومِت</strong></p><p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على شريط الألومنيوم والكرتون بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية. يُحفظ في العبوة الأصلية .</p><p dir="RTL">لا تستخدم هذا الدواء إذا كانت العبوة تالفة أو تظهر عليها علامات الفتح.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محتويات سيقلورومِت</p><p dir="RTL">&bull; المواد الفعالة هي إرتوقليفلوزين وميتفورمين</p><p dir="RTL">o يحتوي كل قرص مُغلّف تركيزه 2.5 ملغم/1000 ملغم على 2.5 ملغم من إرتوقليفلوزين (على شكل إرتوقليفلوزين إل-بيروجلوتاميك أسيد) و 1000 ملغم من الميتفورمين هيدروكلوريد.</p><p>o يحتوي كل قرص مُغلّف تركيزه 2.5 ملغم /1000 ملغم على 2.5 ملغم من إرتوقليفلوزين (على شكل إرتوقليفلوزين إل-بيروجلوتاميك أسيد) و 1000 ملغم من الميتفورمين هيدروكلوريد.</p><p>&nbsp;</p><p dir="RTL">&nbsp;المكونات الأخرى هي:</p><p dir="RTL">o لبّ القرص: بوفيدون (E1201)،&nbsp; السليلوز دقيق التبلور (E460)، كروس بوفيدون (E1202)، لوريل سلفات الصوديوم (E487)، ستيرات المغنيسيوم (E470b).</p><p dir="RTL">o طبقة الغشاء:<br />أقراص سيقلورومِت2.5 ملغم /1000 ملغم و سيقلورومِت7.5 ملغم /1000 ملغم:<br />هيبروميلوز (E464)، هيدروكسي بروبيل سليلوز (E463)، ثاني أكسيد التيتانيوم (E171)،أحمر أكسيد الحديد الأحمر (E172) ، شمع كرنوبا (E903).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الشكل الصيدلاني لسيقلورومِت ووصفه وحجم عبوته</strong><br />&bull; أقراص سيقلورومِت2.5 ملغم /1000 ملغم هي أقراص لونها ورديّ، يبلغ حجمها 19.1&times; 10.6 مم، بيضاوية الشكل، منقوش على أحد جانبيها فقط الرقم&nbsp; &quot;2.5/1000&quot;.</p><p dir="RTL">&bull; أقراص سيقلورومِت7.5 ملغم /1000 ملغم هي أقراص لونها أحمر، يبلغ حجمها 19.1&times; 10.6 مم،&nbsp; بيضاوية الشكل، منقوش على أحد جانبيها فقط الرقم&nbsp; &quot;7.5/1000&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر سيقلورومِت في شرائط من الألومنيوم مصنوعة من Alu / PVC / PA / Alu. تتضمن أحجام &nbsp;العبوات 14 ، 28 ، 56 ، 60 ، 168 ، و 180 قرصًا مغلفًا بغشاء رقيق على شكل شرائط من الألومنيوم غير مُثقبة، وعُلب تحتوي على عبوات عديدة تضم 196 قرص (4 عبوات &nbsp;تحتوي كل منها على 49 قرص) مُغلّف بغشاء رقيق على شكل شرائط من الألومنيوم غير المُثقّبة وعبوات تحتوي على 30 &times; 1 قرص على شكل شريط من الألومنيوم المُثقّبة المُحددة الجرعة. &nbsp;</p><p dir="RTL"><strong>قد لا يتم تسويق جميع أحجام العبوات.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق :</strong></p><p dir="RTL">ميرك شارب و دوم بي. في.</p><p dir="RTL">واردرويج</p><p dir="RTL">٢٠٣١ بي ان هارلم</p><p dir="RTL">هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة الصانعة:</strong></p><p dir="RTL">إم إس دي إنترناشيونال جي إم بي إتش (فرع بورتو ريكو) شركة ذات مسؤولية محددوة</p><p dir="RTL">طريق الولاية</p><p dir="RTL">&nbsp;183 بريدكو</p><p dir="RTL">الحديقة الصناعية</p><p dir="RTL">لاس بيدراس، بورتوريكو 00771، الولايات المتحدة الأمريكية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
لقد تمت مراجعة هذه النشرة بتاريخ  يوليو 2020

للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
للاتصال باالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa
•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.

	
(إن هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك
- إن الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه وضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال

مجلس وزراء الصحة العرب
و اتحاد الصيادلة العرب
تمت الموافقة على نشرة المعلومات الخاصة بالمريض من قبل الهيئة العامة للغذاء والدواء السعودية

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Segluromet 2.5 mg/1,000 mg film-coated tablets
 Segluromet 7.5 mg/1,000 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Segluromet 2.5 mg/1,000 mg film-coated tablets
Each tablet contains 2.5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 1,000 mg of metformin hydrochloride.


Segluromet 7.5 mg/1,000 mg film-coated tablets
Each tablet contains 7.5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 1,000 mg metformin hydrochloride.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).


Segluromet 2.5 mg/1,000 mg film-coated tablets
Pink, 19.1 x 10.6 mm oval, film-coated tablet debossed with “2.5/1000” on one side and plain on the other side.


Segluromet 7.5 mg/1,000 mg film-coated tablets
Red, 19.1 x 10.6 mm oval, film-coated tablet debossed with “7.5/1000” on one side and plain on the other side

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients not adequately controlled on their maximally tolerated dose of metformin alone</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.</p><p>&nbsp;</p><p>(For study results with respect to combinations and effects on glycaemic control, see sections 4.4, 4.5 and 5.1.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose is one tablet twice daily. The dosage should be individualised on the basis of the patient&rsquo;s current regimen, effectiveness, and tolerability using the recommended daily dose of</p><p>5 mg or 15 mg of ertugliflozin, while not exceeding the maximum recommended daily dose of metformin.</p><p>&nbsp;</p><p>In patients with volume depletion, correcting this condition prior to initiation of Segluromet is recommended (see section 4.4).</p><p>&nbsp;</p><p>If a dose is missed, it should be taken as soon as the patient remembers. Patients should not take two doses of Segluromet at the same time.</p><p>&nbsp;</p><p><em><u>Adults with normal renal function </u></em><em><u>(glomerular</u></em><em><u> filtration rate </u></em><em><u>[GFR]</u></em><em><u> </u></em><em><u>&ge; 90 ml/min)</u></em></p><p><em>&nbsp;</em></p><p><em>For patients inadequately controlled on metformin monotherapy or metformin in combination with</em><em> </em><em>other glucose-lowering medicinal products,</em><em> including insulin</em></p><p>The recommended starting dose of Segluromet should provide ertugliflozin 2.5 mg twice daily (5 mg daily dose) and the dose of metformin similar to the dose already being taken. In patients tolerating a total daily dose of ertugliflozin 5 mg, the dose can be increased to a total daily dose of ertugliflozin 15 mg if additional glycaemic control is needed.</p><p>&nbsp;</p><p><em>For patients switching from separate tablets of ertugliflozin and metformin</em></p><p>Patients switching from separate tablets of ertugliflozin (5 mg or 15 mg total daily dose) and metformin to Segluromet should receive the same daily dose of ertugliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.</p><p>&nbsp;</p><p>When Segluromet is used in combination with insulin or an insulin secretagogue, a lower dose of insulin or the insulin secretagogue may be required to reduce the risk of hypoglycaemia (see sections 4.4, 4.5, and 4.8).</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>A GFR should be assessed before initiation of treatment with metformin-containing products and at least annually thereafter. In patients at increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g., every 3-6 months.</p><p>&nbsp;</p><p>Initiation of this medicinal product is not recommended in patients with a GFR less than 60 ml/min (see section 4.4).</p><p>&nbsp;</p><p>The maximum daily dose of metformin should preferably be divided into 2-3 daily doses. Factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of metformin in patients with GFR &lt; 60 ml/min.</p><p>&nbsp;</p><p>If no adequate strength of Segluromet is available, individual monocomponents should be used instead of the fixed-dose combination.</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>GFR ml/min</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Metformin</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Ertugliflozin</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>60-89</em></p></td><td style="vertical-align:top"><p><em>Maximum daily dose is 3,000 mg.</em><em> </em><em>Dose reduction may be considered in</em><em> </em><em>relation to declining renal function.</em></p></td><td style="vertical-align:top"><p><em>Maximum daily dose is 15</em><em> </em><em>mg.</em></p></td></tr><tr><td style="vertical-align:top"><p><em>45-59</em></p></td><td style="vertical-align:top"><p><em>Maximum daily dose is </em><em>2,000</em><em> mg.</em></p><p><em>The starting dose is at most half of the</em><em> </em><em>maximum dose.</em></p></td><td style="vertical-align:top"><p><em>Initiation is not recommended in</em><em> </em><em>patients with </em><em>a glomerular filtration rate less than 60 ml/min (see section 4.4).</em></p><p>&nbsp;</p><p><em>Discontinue when GFR </em><em>is persistently less than 45 ml/min.</em></p></td></tr><tr><td style="vertical-align:top"><p><em>30-44</em></p></td><td style="vertical-align:top"><p><em>Maximum daily dose is 1,000 mg.</em></p><p><em>The starting dose is at most half of the</em><em> </em><em>maximum dose.</em></p></td><td style="vertical-align:top"><p><em>Not recommended.</em></p></td></tr><tr><td style="vertical-align:top"><p><em>&lt; 30</em></p></td><td style="vertical-align:top"><p><em>Metformin is contraindicated.</em></p></td><td style="vertical-align:top"><p><em>Not recommended.</em></p></td></tr></tbody></table><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Segluromet is contraindicated in patients with hepatic impairment (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em>Elderly (&ge; 65 years old)</em></p><p>Elderly patients are more likely to have decreased renal function. Because renal function abnormalities can occur after initiating ertugliflozin, and metformin is known to be substantially excreted by the kidneys, Segluromet should be used with caution in the elderly. Regular assessment of renal function</p><p>is necessary to aid in prevention of metformin-associated lactic acidosis, particularly in elderly patients (see section 4.4). Renal function and risk of volume depletion should be taken into account (see sections 4.4 and 4.8).</p><p>There is limited experience with Segluromet in patients &ge; 75 years of age.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Segluromet in children under 18 years of age have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Segluromet should be taken orally twice daily with meals to reduce the gastrointestinal adverse reactions associated with metformin. In case of swallowing difficulties, the tablet could be broken or crushed as it is an immediate-release dosage form.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1;
-	any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis [DKA]);
-	diabetic pre coma;
 
-	severe renal failure (GFR less than 30 ml/min), end-stage renal disease (ESRD), or patients on dialysis (see section 4.4);
-	acute condition with the potential to alter renal function, such as:
-	dehydration,
-	severe infection,
-	shock;
-	acute or chronic disease that may cause tissue hypoxia, such as:
-	cardiac or respiratory failure,
-	recent myocardial infarction,
-	shock;
-	hepatic impairment;
-	acute alcohol intoxication, alcoholism.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Segluromet should not be used in patients with type 1 diabetes mellitus.</p><p>&nbsp;</p><p><u>Lactic acidosis</u></p><p>Lactic acidosis, a very rare but serious metabolic complication, most often occurs at acute worsening of renal function or cardiorespiratory illness or sepsis. Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis.</p><p>&nbsp;</p><p>In case of dehydration (severe vomiting, diarrhoea, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended.</p><p>&nbsp;</p><p>Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and non-steroidal anti-inflammatory drugs [NSAIDs]) should be initiated with caution in metformin- treated patients. Other risk factors for lactic acidosis are excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p>Patients and/or care-givers should be informed of the risk of lactic acidosis. Lactic acidosis is characterised by acidotic dyspnoea, abdominal pain, muscle cramps, asthenia and hypothermia followed by coma. In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention. Diagnostic laboratory findings are decreased blood pH (&lt; 7.35), increased plasma lactate levels (&gt; 5 mmol/l) and an increased anion gap and lactate/pyruvate ratio.</p><p>&nbsp;</p><p><u>Administration of iodinated contrast agents</u></p><p>Intravascular administration of iodinated contrast agents may lead to contrast-induced nephropathy, resulting in metformin accumulation and an increased risk of lactic acidosis. Segluromet should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable (see sections 4.2 and 4.5).</p><p>&nbsp;</p><p><u>Renal function</u></p><p>The efficacy of ertugliflozin is dependent on renal function, and efficacy is reduced in patients who have moderate renal impairment and likely absent in patients with severe renal impairment (see section 4.2).</p><p>&nbsp;</p><p>Segluromet should not be initiated in patients with a GFR below 60 ml/min. Segluromet should be discontinued when GFR is persistently below 45 ml/min due to a reduction of efficacy.</p><p>&nbsp;</p><p>GFR should be assessed before treatment initiation and regularly thereafter (see section 4.2). More frequent renal function monitoring is recommended in patients with a GFR below 60 ml/min.</p><p>&nbsp;</p><p>Metformin is contraindicated in patients with GFR &lt; 30 ml/min and should be temporarily discontinued in the presence of conditions that alter renal function (see section 4.3).</p><p>&nbsp;</p><p><u>Surgery</u></p><p>Segluromet must be discontinued at the time of surgery under general, spinal, or epidural anaesthesia. Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable.</p><p>&nbsp;</p><p><u>Hypotension/Volume depletion</u></p><p>Ertugliflozin causes an osmotic diuresis, which may lead to intravascular volume contraction. Therefore, symptomatic hypotension may occur after initiating Segluromet (see section 4.8), particularly in patients with impaired renal function (eGFR less than 60 ml/min/1.73 m<sup>2</sup> or a CrCl less than 60 ml/min), elderly patients (&ge; 65 years), patients on diuretics, or patients on anti-hypertensive therapy with a history of hypotension. Before initiating Segluromet, volume status should be assessed and corrected if indicated. Monitor for signs and symptoms after initiating therapy.</p><p>&nbsp;</p><p>Due to its mechanism of action, ertugliflozin induces an osmotic diuresis and increases serum creatinine and decreases eGFR. Increases in serum creatinine and decreases in eGFR were greater in patients with moderate renal impairment (see section 4.8).</p><p>&nbsp;</p><p>In case of conditions that may lead to fluid loss (e.g., gastrointestinal illness), careful monitoring of volume status (e.g., physical examination, blood pressure measurements, laboratory tests including haematocrit) and electrolytes is recommended for patients receiving ertugliflozin. Temporary interruption of treatment with Segluromet should be considered until the fluid loss is corrected.</p><p>&nbsp;</p><p><u>Diabetic ketoacidosis</u></p><p>Rare cases of DKA, including life-threatening and fatal cases, have been reported in clinical trials and post-marketing in patients treated with sodium glucose co-transporter-2 (SGLT2) inhibitors, and cases have been reported in clinical trials with ertugliflozin. In a number of cases, the presentation of the condition was atypical with only moderately increased blood glucose values, below 14 mmol/l</p><p>(250 mg/dl). It is not known if DKA is more likely to occur with higher doses of ertugliflozin.</p><p>&nbsp;</p><p>The risk of diabetic ketoacidosis must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue, or sleepiness. Patients should be assessed for ketoacidosis immediately if these symptoms occur, regardless of blood glucose level.</p><p>&nbsp;</p><p>In patients where DKA is suspected or diagnosed, treatment with Segluromet should be discontinued immediately.</p><p>&nbsp;</p><p>Treatment should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses. Monitoring of ketones is recommended in these patients. Measurement of blood ketone levels is preferred to urine. Treatment with Segluromet may be restarted when the ketone values are normal and the patient&rsquo;s condition has stabilised.</p><p>&nbsp;</p><p>Before initiating Segluromet, factors in the patient history that may predispose to ketoacidosis should be considered.</p><p>&nbsp;</p><p>Patients who may be at higher risk of DKA include patients with a low beta-cell function reserve (e.g., type 2 diabetes patients with low C-peptide or latent autoimmune diabetes in adults (LADA) or patients with a history of pancreatitis), patients with conditions that lead to restricted food intake or severe dehydration, patients for whom insulin doses are reduced and patients with increased insulin requirements due to acute medical illness, surgery, or alcohol abuse. SGLT2 inhibitors should be used with caution in these patients.</p><p>&nbsp;</p><p>Restarting SGLT2 inhibitor treatment in patients with previous DKA while on SGLT2 inhibitor treatment is not recommended, unless another clear precipitating factor is identified and resolved.</p><p>&nbsp;</p><p>The safety and efficacy of Segluromet in patients with type 1 diabetes have not been established and Segluromet should not be used for treatment of patients with type 1 diabetes. Limited data from clinical trials suggest that DKA occurs with common frequency when patients with type 1 diabetes are treated with SGLT2 inhibitors.</p><p>&nbsp;</p><p><u>Lower limb amputations</u></p><p>In an ongoing clinical study of ertugliflozin added to existing therapy in type 2 diabetes patients with a history of established cardiovascular disease, an approximately 1.2-1.6-fold increase in cases of lower limb amputation (primarily of the toe) has been observed in patients treated with ertugliflozin. An increase in cases of lower limb amputation (primarily of the toe) has also been observed in long-term clinical studies with another SGLT2 inhibitor. As an underlying mechanism has not been established, risk factors, apart from general risk factors, for amputation are unknown.</p><p>&nbsp;</p><p>Before initiating ertugliflozin/metformin, consider factors in the patient history that may increase the risk for amputation. As precautionary measures, consideration should be given to carefully monitoring patients with a higher risk for amputation events and counselling patients about the importance of routine preventative foot care and maintaining adequate hydration. Consideration may also be given to stopping treatment with ertugliflozin/metformin in patients who develop events which may precede amputation such as lower-extremity skin ulcer, infection, osteomyelitis or gangrene.</p><p>&nbsp;</p><p><u>Hypoglycaemia with concomitant use of insulin and insulin secretagogues</u></p><p>Ertugliflozin may increase the risk of hypoglycaemia when used in combination with insulin and/or an insulin secretagogue, which are known to cause hypoglycaemia (see section 4.8). Therefore, a lower dose of insulin or insulin secretagogue may be required to minimise the risk of hypoglycaemia when used in combination with Segluromet (see sections 4.2 and 4.5).</p><p>&nbsp;</p><p><u>Genital mycotic infections</u></p><p>Ertugliflozin increases the risk of genital mycotic infections. In trials with SGLT2 inhibitors, patients with a history of genital mycotic infections and uncircumcised males were more likely to develop genital mycotic infections (see section 4.8). Patients should be monitored and treated appropriately.</p><p>&nbsp;</p><p><u>Urinary tract infections</u></p><p>Urinary glucose excretion may be associated with an increased risk of urinary tract infections.</p><p>The incidence of urinary tract infections was not notably different in the ertugliflozin 5 mg and 15 mg groups (4.0% and 4.1%) and the placebo group (3.9%). Most of the events were mild or moderate and no serious case was reported. Temporary interruption of ertugliflozin should be considered when treating pyelonephritis or urosepsis.</p><p>&nbsp;</p><p><u>Necrotising fasciitis of the perineum (Fournier&rsquo;s gangrene)</u></p><p>Post-marketing cases of necrotising fasciitis of the perineum, (also known as Fournier&rsquo;s gangrene), have been reported in female and male patients taking SGLT2 inhibitors. This is a rare but serious and potentially life-threatening event that requires urgent surgical intervention and antibiotic treatment.</p><p>&nbsp;</p><p>Patients should be advised to seek medical attention if they experience a combination of symptoms of pain, tenderness, erythema, or swelling in the genital or perineal area, with fever or malaise. Be aware that either uro-genital infection or perineal abscess may precede necrotising fasciitis. If Fournier&rsquo;s gangrene is suspected, Segluromet should be discontinued and prompt treatment (including antibiotics and surgical debridement) should be instituted.</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>Elderly patients may be at an increased risk of volume depletion. Patients 65 years and older treated with ertugliflozin had a higher incidence of adverse reactions related to volume depletion compared to younger patients. The risk of metformin-associated lactic acidosis increases with the patient&rsquo;s age because elderly patients have a greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Segluromet is expected to have diminished efficacy in elderly patients with renal impairment (see sections 4.2 and 4.8). Assess renal function more frequently in elderly patients.</p><p>&nbsp;</p><p><u>Cardiac failure</u></p><p>Experience in New York Heart Association (NYHA) class I-II is limited, and there is no experience in clinical studies with ertugliflozin in NYHA class III-IV.</p><p>&nbsp;</p><p><u>Urine laboratory assessments</u></p><p>Due to the mechanism of action of ertugliflozin, patients taking Segluromet will test positive for glucose in their urine. Alternative methods should be used to monitor glycaemic control.</p><p>&nbsp;</p><p><u>Interference with 1,5 anhydroglucitol (1,5-AG) assay</u></p><p>Monitoring glycaemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycaemic control in patients taking medicines containing an SGLT2 inhibitor. Alternative methods should be used to monitor glycaemic control.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacokinetic drug interaction studies with Segluromet have not been performed; however, such studies have been conducted with ertugliflozin and metformin, the individual active substances of Segluromet.</p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>&nbsp;</p><p><em><u>Pharmacodynamic interactions</u></em></p><p><em>&nbsp;</em></p><p><em>Diuretics</em></p><p>Ertugliflozin may add to the diuretic effect of diuretics and may increase the risk of dehydration and hypotension (see section 4.4).</p><p>&nbsp;</p><p><em>Insulin and insulin secretagogues</em></p><p>Insulin and insulin secretagogues, such as sulphonylureas, cause hypoglycaemia. Ertugliflozin may increase the risk of hypoglycaemia when used in combination with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with Segluromet (see sections 4.2, 4.4, and 4.8).</p><p>&nbsp;</p><p><em><u>Pharmacokinetic interactions</u></em></p><p><em>&nbsp;</em></p><p><em><u>Effects of other medicinal products on the pharmacokinetics of ertugliflozin</u></em></p><p>Metabolism by UGT1A9 and UGT2B7 is the primary clearance mechanism for ertugliflozin.</p><p>&nbsp;</p><p>Interaction studies conducted in healthy subjects, using a single dose design, suggest that the pharmacokinetics of ertugliflozin are not altered by sitagliptin, metformin, glimepiride, or simvastatin.</p><p>&nbsp;</p><p>Multiple-dose administration of rifampin (a UGT and CYP inducer) decreases ertugliflozin AUC and Cmax&nbsp;by 39% and 15%, respectively. This decrease in exposure is not considered clinically relevant and therefore, no dose adjustment is recommended. A clinically relevant effect with other inducers (e.g., carbamazepine, phenytoin, phenobarbital) is not expected.</p><p>&nbsp;</p><p>The impact of UGT inhibitors on the pharmacokinetics of ertugliflozin has not been studied clinically, but potential increase in ertugliflozin exposure due to UGT inhibition is not considered to be clinically relevant.</p><p>&nbsp;</p><p><em><u>Effects of ertugliflozin on the pharmacokinetics of other medicinal products</u></em></p><p>Interaction studies conducted in healthy volunteers suggest that ertugliflozin had no clinically relevant effect on the pharmacokinetics of sitagliptin, metformin, and glimepiride.</p><p>&nbsp;</p><p>Coadministration of simvastatin with ertugliflozin resulted in a 24% and 19% increase in AUC and Cmax&nbsp;of simvastatin, respectively, and 30% and 16% increase in AUC and Cmax&nbsp;of simvastatin acid, respectively. The mechanism for the small increases in simvastatin and simvastatin acid is unknown and is not perpetrated through OATP inhibition by ertugliflozin. These increases are not considered to be clinically meaningful.</p><p>&nbsp;</p><p><u>Metformin</u></p><p>&nbsp;</p><p><em><u>Concomitant use not recommended</u></em></p><p><em>&nbsp;</em></p><p><em>Alcohol</em></p><p>Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in cases of fasting, malnutrition or hepatic impairment.</p><p>&nbsp;</p><p><em>Iodinated contrast agents</em></p><p>Segluromet must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><em><u>Combinations requiring</u></em><em><u> </u></em><em><u>precautions for use</u></em></p><p>Some medicinal products can adversely affect renal function, which may increase the risk of lactic acidosis, e.g., NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors,</p><p>&nbsp;</p><p>angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. When starting or using such products in combination with metformin, close monitoring of renal function is necessary.</p><p>&nbsp;</p><p><em>Organic cation transporters (OCT)</em></p><p>Metformin is a substrate of both transporters OCT1 and OCT2.</p><p>&nbsp;</p><p>Coadministration of metformin with</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprime, vandetanib, isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhibitors of both OCT1 and OCT2 (such as crizotinib, olaparib) may alter efficacy and renal elimination of metformin.</p><p>&nbsp;</p><p>Caution is therefore advised, especially in patients with renal impairment, when these drugs are coadministered with metformin, as metformin plasma concentration may increase. If needed, dose adjustment of metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin.</p><p>&nbsp;</p><p>Glucocorticoids (given by systemic and local routes), beta 2 agonists, and diuretics have intrinsic hyperglycaemic activity. The patient should be informed and more frequent blood glucose monitoring performed, especially at the beginning of treatment with such medicinal products. If necessary, the dose of the antihyperglycaemic medicinal product should be adjusted during therapy with the other medicinal product and on its discontinuation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no data from the use of Segluromet in pregnant women.</p><p>&nbsp;</p><p>A limited amount of data suggests the use of metformin in pregnant women is not associated with an increased risk of congenital malformations. Animal studies with metformin do not indicate harmful effects with respect to pregnancy, embryonic or foetal development, parturition or post-natal development (see section 5.3).</p><p>&nbsp;</p><p>There are limited data from the use of ertugliflozin in pregnant women. Based on results from animal studies, ertugliflozin may affect renal development and maturation (see section 5.3).Therefore, Segluromet should not be used during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>There is no information regarding the presence of ertugliflozin in human milk, the effects on the breast-fed infant, or the effects on milk production. Metformin is present in human breast milk.</p><p>Ertugliflozin and metformin are present in the milk of lactating rats. Ertugliflozin caused effects in the offspring of lactating rats.</p><p>&nbsp;</p><p>Pharmacologically mediated effects were observed in juvenile rats treated with ertugliflozin (see section 5.3). Since human kidney maturation occurs <em>in utero </em>and during the first 2 years of life when exposure from breast-feeding may occur, a risk to newborns/infants cannot be excluded. Segluromet should not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>The effect of Segluromet on fertility in humans has not been studied. No effects of ertugliflozin or metformin on fertility were observed in animal studies (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Segluromet has no or negligible influence on the ability to drive and use machines. Patients should be alerted to the risk of hypoglycaemia when Segluromet is used in combination with insulin or an insulin secretagogue and to the elevated risk of adverse reactions related to volume depletion, such as postural dizziness (see sections 4.2, 4.4, and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p><em><u>Ertugliflozin and Metformin</u></em></p><p>The safety of concomitantly administered ertugliflozin and metformin has been evaluated in</p><p>1,083 patients with type 2 diabetes mellitus treated for 26 weeks in a pool of two placebo-controlled trials: as ertugliflozin add on therapy to metformin and as ertugliflozin add-on therapy to sitagliptin and metformin (see section 5.1). The incidence and type of adverse reactions in these two trials were similar to the adverse reactions seen with ertugliflozin. There were no additional adverse reactions identified in the pooling of these two placebo-controlled trials that included metformin relative to the three placebo-controlled studies with ertugliflozin (see below).</p><p>&nbsp;</p><p><em><u>Ertugliflozin</u></em></p><p><em>&nbsp;</em></p><p><em>Pool</em><em> of placebo-controlled trials</em></p><p>The primary assessment of safety was conducted in a pool of three 26-week, placebo-controlled trials.</p><p>Ertugliflozin was used as monotherapy in one trial and as add-on therapy in two trials (see section 5.1). These data reflect exposure of 1,029 patients to ertugliflozin with a mean exposure</p><p>duration of approximately 25 weeks. Patients received ertugliflozin 5 mg (N=519), ertugliflozin 15 mg (N=510), or placebo (N=515) once daily.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions across the clinical program were vulvovaginal mycotic infection, and other female genital mycotic infections. Serious diabetic ketoacidosis occurred rarely.</p><p>See &ldquo;Description of selected adverse reactions&rdquo; for frequencies and see section 4.4.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions listed below are classified according to frequency and system organ class (SOC). Frequency categories are defined according to the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 1: Adverse reactions</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p><p>Frequency</p></td><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common Common</p></td><td style="vertical-align:top"><p>Vulvovaginal mycotic infection and other female genital mycotic infections*,&dagger;,1</p><p><strong>&nbsp;</strong></p><p>Balanitis candida and other male genital mycotic infections*,&dagger;,1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common Rare Very rare</p></td><td style="vertical-align:top"><p>Hypoglycaemia*,&dagger;,1</p><p><strong>&nbsp;</strong></p><p>Diabetic ketoacidosis*,&dagger;,1</p><p><strong>&nbsp;</strong></p><p>Lactic acidosis*,2, Vitamin B12&nbsp;deficiency&Dagger;,2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Taste disturbance2</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Volume depletion*,&dagger;,1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Gastrointestinal symptoms&sect;,2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Liver function test abnormal2, Hepatitis2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Erythema2, Pruritus2, Urticaria2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common Uncommon</p></td><td style="vertical-align:top"><p>Increased urination&para;,1</p><p><strong>&nbsp;</strong></p><p>Dysuria1, Blood creatinine increased/Glomerular filtration rate decreased&dagger;,1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vulvovaginal pruritus1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and</strong><strong> administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Thirst#,1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Serum lipids changed&THORN;,1, Haemoglobin increased&szlig;,1, BUN increased&agrave;,1</p></td></tr></tbody></table><p>1&nbsp;&nbsp; &nbsp;Adverse reaction with ertugliflozin.</p><p>2&nbsp;&nbsp; &nbsp;Adverse reaction with metformin.</p><p>* &nbsp;See Section 4.4.</p><p>&dagger;&nbsp;&nbsp; &nbsp;See subsections below for additional information.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;Long-term treatment with metformin has been associated with a decrease in vitamin B12&nbsp;absorption, which may very rarely result in clinically significant vitamin B12&nbsp;deficiency (e.g., megaloblastic anaemia).</p><p>&sect;&nbsp;&nbsp; &nbsp;Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite occur most</p><p>frequently during initiation of therapy and resolve spontaneously in most cases.</p><p>&para;&nbsp; &nbsp;Includes: pollakiuria, micturition urgency, polyuria, urine output increased, and nocturia.</p><p>#&nbsp; &nbsp;Includes: thirst and polydipsia.</p><p>&THORN;&nbsp;&nbsp;&nbsp; Mean percent changes from baseline for ertugliflozin 5 mg and 15 mg versus placebo, respectively, were LDL-C 5.8% and 8.4% versus 3.2%; total cholesterol 2.8% and 5.7% versus 1.1%; however, HDL-C 6.2% and 7.6% versus 1.9%. Median percent changes from baseline for ertugliflozin 5 mg and 15 mg versus placebo, respectively, were triglycerides -3.9% and -1.7% versus 4.5%.</p><p>&szlig;&nbsp;&nbsp; &nbsp;The proportion of subjects having at least 1 increase in haemoglobin &gt; 2.0 g/dL was higher in the ertugliflozin 5 mg and 15 mg groups (4.7% and 4.1%, respectively) compared to the placebo group (0.6%).</p><p>&agrave;&nbsp;&nbsp; &nbsp;The proportion of subjects having any occurrence of BUN values &ge; 50% increase and value &gt;ULN was numerically higher in the ertugliflozin 5 mg group and higher in the 15 mg group (7.9% and 9.8%, respectively) relative to the</p><p>placebo group (5.1%).</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Volume depletion (ertugliflozin)</u></em></p><p>Ertugliflozin causes an osmotic diuresis, which may lead to intravascular volume contraction and adverse reactions related to volume depletion. In the pool of placebo-controlled studies, the incidence of adverse events related to volume depletion (dehydration, dizziness postural, presyncope, syncope, hypotension, and orthostatic hypotension) was low (&lt; 2%) and not notably different across the ertugliflozin and placebo groups. In the subgroup analyses in the broader pool of Phase 3 studies, subjects with eGFR &lt; 60 mL/min/1.73 m2, subjects &ge; 65 years of age and subjects on diuretics had a higher incidence of volume depletion in the ertugliflozin groups relative to the comparator group (see sections 4.2 and 4.4). In subjects with eGFR &lt; 60 mL/min/1.73 m2, the incidence was 5.1%, 2.6%, and 0.5% for ertugliflozin 5 mg, ertugliflozin 15 mg, and the comparator group and for subjects with</p><p>eGFR 45 to &lt; 60 mL/min/1.73 m2, the incidence was 6.4%, 3.7%, and 0% respectively.</p><p>&nbsp;</p><p><em><u>Hypoglycaemia</u></em><em><u> (ertugliflozin)</u></em></p><p>In the pool of placebo-controlled studies, the incidence of documented hypoglycaemia was increased for ertugliflozin 5 mg and 15 mg (5.0% and 4.5%) compared to placebo (2.9%). In this population, the</p><p>&nbsp;</p><p>incidence of severe hypoglycaemia was 0.4% in each group. When ertugliflozin was used as monotherapy, the incidence of hypoglycaemic events in the ertugliflozin groups was 2.6% in both groups and 0.7% in the placebo group. When used as add-on to metformin, the incidence of hypoglycaemic events was 7.2% in the ertugliflozin 5 mg group, 7.8% in the ertugliflozin 15 mg group and 4.3% in the placebo group.</p><p>&nbsp;</p><p>When ertugliflozin was added to metformin and compared to sulphonylurea, the incidence of hypoglycaemia was higher for the sulphonylurea (27%) compared to ertugliflozin (5.6% and 8.2% for ertugliflozin 5 mg and 15 mg, respectively).</p><p>&nbsp;</p><p>In patients with moderate renal impairment taking insulins, SU, or meglitinides as background medication, documented hypoglycaemia was 36%, 27% and 36% for ertugliflozin 5 mg, ertugliflozin</p><p>15 mg, and placebo, respectively (see sections 4.2, 4.4, and 4.5).</p><p>&nbsp;</p><p><em><u>Diabetic ketoacidosis (ertugliflozin)</u></em></p><p>Across the clinical program for ertugliflozin, ketoacidosis was identified in 3 of 3,409 (0.1%) ertugliflozin-treated patients and 0.0% of comparator-treated patients (see section 4.4).</p><p>&nbsp;</p><p><em><u>Blood creatinine increased/Glomerular filtration rate decreased and </u></em><em><u>renal-related</u></em><em><u> events</u></em><em> </em><em><u>(ertugliflozin)</u></em></p><p>Initial increases in mean creatinine and decreases in mean eGFR in patients treated with ertugliflozin were generally transient during continuous treatment. Patients with moderate renal impairment at baseline had larger mean changes that did not return to baseline at Week 26; these changes reversed after treatment discontinuation.</p><p>&nbsp;</p><p>Renal-related adverse reactions (e.g., acute kidney injury, renal impairment, acute prerenal failure) may occur in patients treated with ertugliflozin, particularly in patients with moderate renal impairment where the incidence of renal-related adverse reactions was 2.5%, 1.3%, and 0.6% in patients treated with ertugliflozin 5 mg, ertugliflozin 15 mg, and placebo, respectively.</p><p>&nbsp;</p><p><em><u>Genital mycotic infections (ertugliflozin)</u></em></p><p>In the pool of three placebo-controlled clinical trials, female genital mycotic infections (e.g., genital candidiasis, genital infection fungal, vaginal infection, vulvitis, vulvovaginal candidiasis, vulvovaginal mycotic infection, vulvovaginitis) occurred in 9.1%, 12%, and 3.0% of females treated with ertugliflozin 5 mg, ertugliflozin 15 mg, and placebo, respectively. In females, discontinuation due to genital mycotic infections occurred in 0.6% and 0% of patients treated with ertugliflozin and placebo, respectively (see section 4.4).</p><p>&nbsp;</p><p>In the same pool, male genital mycotic infections (e.g., balanitis candida, balanoposthitis, genital infection, genital infection fungal) occurred in 3.7%, 4.2%, and 0.4% of males treated with ertugliflozin 5 mg, ertugliflozin 15 mg, and placebo, respectively. Male genital mycotic infections occurred more commonly in uncircumcised males. In males, discontinuations due to genital mycotic infections occurred in 0.2% and 0% of patients treated with ertugliflozin and placebo, respectively. In rare instances, phimosis was reported and sometimes circumcision was performed (see section 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of an overdose with Segluromet, employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment) as dictated by the patient&rsquo;s clinical status.</p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>Ertugliflozin did not show any toxicity in healthy subjects at single oral doses up to 300 mg and multiple doses up to 100 mg daily for 2 weeks. No potential acute symptoms and signs of overdose were identified. Removal of ertugliflozin by haemodialysis has not been studied.</p><p>&nbsp;</p><p><u>Metformin</u></p><p>Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 g. Hypoglycaemia was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases (see section 4.4). Lactic acidosis is a medical emergency and must be treated in a hospital. Metformin is dialyzable with a clearance of up to 170 ml/min under good haemodynamic conditions. Therefore, haemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdose is suspected.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD23.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Segluromet combines two antihyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: ertugliflozin, a SGLT2 inhibitor, and metformin hydrochloride, a member of the biguanide class.</p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is a potent, selective, and reversible inhibitor of SGLT2. By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.</p><p>&nbsp;</p><p><u>Metformin</u></p><p>Metformin is an antihyperglycaemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and post-prandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycaemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilisation. Unlike sulphonylureas, metformin does not produce hypoglycaemia in either patients with type 2 diabetes or normal subjects, except in special circumstances (see section 4.5), and does not cause hyperinsulinaemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><em><u>Ertugliflozin</u></em></p><p><em>&nbsp;</em></p><p><em>Urinary glucose excretion and urinary volume</em></p><p>Dose-dependent increases in the amount of glucose excreted in urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following single- and multiple-dose administration of ertugliflozin. Dose-response modelling indicates that ertugliflozin 5 mg and 15 mg result in near maximal urinary glucose excretion (UGE) in patients with type 2 diabetes mellitus, providing 87% and 96% of maximal inhibition, respectively.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Ertugliflozin in combination with metformin</em></p><p>The efficacy and safety of ertugliflozin in combination with metformin have been studied in</p><p>4 multi-centre, randomised, double-blind, placebo- and active comparator-controlled, Phase 3 clinical studies involving 3,643 patients with type 2 diabetes. Across the four studies, the racial distribution ranged from 66.2% to 80.3% White, 10.6% to 20.3% Asian, 1.9% to 10.3% Black, and 4.5% to 7.4% other. Hispanic or Latino patients comprised 15.6% to 34.5% of the population. The mean age of the patients across these four studies ranged from 55.1 to 59.1 years (range 21 years to 86 years); 15.6% to 29.9% of patients were &ge;65 years of age and 0.6% to 3.8% were &ge;75 years of age.</p><p>&nbsp;</p><p><em>Ertugliflozin as add-on combination</em><em> </em><em>therapy with </em><em>metformin</em></p><p>A total of 621 patients with type 2 diabetes inadequately controlled on metformin monotherapy (&ge; 1,500 mg/day) participated in a randomised, double-blind, multi-centre, 26-week, placebo-</p><p>controlled study to evaluate the efficacy and safety of ertugliflozin in combination with metformin. Patients were randomised to ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo administered once daily in addition to continuation of background metformin therapy (see Table 2).</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 2: Results at Week 26 from a placebo-controlled study for ertugliflozin used in combination with metformin*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Ertugliflozin </strong><strong>5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Ertugliflozin 15</strong><strong> </strong><strong>mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 207</strong></p></td><td style="vertical-align:top"><p><strong>N = 205</strong></p></td><td style="vertical-align:top"><p><strong>N = 209</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>8.2</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-0.7</p></td><td style="vertical-align:top"><p>-0.9</p></td><td rowspan="2" style="vertical-align:top"><p>-0.0</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-0.7&Dagger; (-0.9, -0.5)</p></td><td style="vertical-align:top"><p>-0.9&Dagger; (-1.1, -0.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients [N (%)] with HbA1c &lt; 7%</strong></p></td><td style="vertical-align:top"><p>73 (35.3)&sect;</p></td><td style="vertical-align:top"><p>82 (40.0)&sect;</p></td><td style="vertical-align:top"><p>33 (15.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 207</strong></p></td><td style="vertical-align:top"><p><strong>N = 205</strong></p></td><td style="vertical-align:top"><p><strong>N = 209</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>84.9</p></td><td style="vertical-align:top"><p>85.3</p></td><td style="vertical-align:top"><p>84.5</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-3.0</p></td><td style="vertical-align:top"><p>-2.9</p></td><td rowspan="2" style="vertical-align:top"><p>-1.3</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-1.7&Dagger; (-2.2, -1.1)</p></td><td style="vertical-align:top"><p>-1.6&Dagger; (-2.2, -1.0)</p></td></tr></tbody></table><p>* &nbsp;N includes all randomised, treated patients who had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp;&nbsp; &nbsp;Least squares means adjusted for treatment, time, prior antihyperglycemic medication, baseline eGFR, menopausal status randomization stratum, and the interaction of time by treatment.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;p&pound; 0.001 compared to placebo.</p><p>&sect;&nbsp;&nbsp; &nbsp;p&lt; 0.001 compared to placebo (based on adjusted odds ratio comparisons from a logistic regression model using multiple imputation for missing data values).</p><p>&nbsp;</p><p><em>Factorial study with ertugliflozin and sitagliptin as add-on</em><em> combination therapy with metformin</em></p><p>A total of 1,233 patients with type 2 diabetes participated in a randomised, double-blind, multi-centre, 26-week, active-controlled study to evaluate the efficacy and safety of ertugliflozin 5 mg or 15 mg in combination with sitagliptin 100 mg compared to the individual components. Patients with type 2 diabetes inadequately controlled on metformin monotherapy (&ge; 1,500 mg/day) were randomised to one of five active-treatment arms: ertugliflozin 5 mg or 15 mg, sitagliptin 100 mg, or sitagliptin 100 mg in combination with 5 mg or 15 mg ertugliflozin administered once daily in addition to continuation of background metformin therapy (see Table 3).</p><p>&nbsp;</p><p>Table 3: Results at Week 26 from a factorial study with ertugliflozin and sitagliptin as add-on combination therapy with metformin compared to individual components alone*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Ertugliflozin</strong><strong> </strong><strong>5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Ertugliflozin</strong><strong> </strong><strong>15 mg</strong></p></td><td style="vertical-align:top"><p><strong>Sitagliptin</strong><strong> </strong><strong>100 mg</strong></p></td><td style="vertical-align:top"><p><strong>Ertugliflozin </strong><strong>5 mg + Sitagliptin 100 mg</strong></p></td><td style="vertical-align:top"><p><strong>Ertugliflozin</strong><strong> 15 mg</strong></p><p><strong>+ Sitagliptin 100 mg</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p><p>Baseline (mean)</p><p>Change from baseline (LS mean&dagger;) Difference from</p><p>Sitagliptin</p><p>Ertugliflozin 5 mg</p><p>Ertugliflozin 15 mg (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p><strong>N = 250</strong></p><p>8.6</p><p>-1.0</p></td><td style="vertical-align:top"><p><strong>N = 248</strong></p><p>8.6</p><p>-1.1</p></td><td style="vertical-align:top"><p><strong>N = 247</strong></p><p>8.5</p><p>-1.1</p></td><td style="vertical-align:top"><p><strong>N = 243</strong></p><p>8.6</p><p>-1.5</p><p><strong>&nbsp;</strong></p><p>-0.4&Dagger; (-0.6, -0.3)</p><p>-0.5&Dagger; (-0.6, -0.3)</p></td><td style="vertical-align:top"><p><strong>N = 244</strong></p><p>8.6</p><p>-1.5</p><p><strong>&nbsp;</strong></p><p>-0.5&Dagger; (-0.6, -0.3)</p><p><strong>&nbsp;</strong></p><p>-0.4&Dagger; (-0.6, -0.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Patients [N (%)] with HbA1c &lt; 7%</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>66 (26.4)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>79 (31.9)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>81 (32.8)</p></td><td style="vertical-align:top"><p>127&sect; (52.3)</p></td><td style="vertical-align:top"><p>120&sect; (49.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 250</strong></p></td><td style="vertical-align:top"><p><strong>N = 248</strong></p></td><td style="vertical-align:top"><p><strong>N = 247</strong></p></td><td style="vertical-align:top"><p><strong>N = 243</strong></p></td><td style="vertical-align:top"><p><strong>N = 244</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>88.6</p></td><td style="vertical-align:top"><p>88.0</p></td><td style="vertical-align:top"><p>89.8</p></td><td style="vertical-align:top"><p>89.5</p></td><td style="vertical-align:top"><p>87.5</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td rowspan="3" style="vertical-align:top"><p>-2.7</p></td><td rowspan="3" style="vertical-align:top"><p>-3.7</p></td><td rowspan="3" style="vertical-align:top"><p>-0.7</p></td><td style="vertical-align:top"><p>-2.5</p></td><td style="vertical-align:top"><p>-2.9</p></td></tr><tr><td style="vertical-align:top"><p>Difference from Sitagliptin</p></td><td rowspan="2" style="vertical-align:top"><p>-1.8&Dagger; (-2.5, -1.2)</p></td><td rowspan="2" style="vertical-align:top"><p>-2.3&Dagger; (-2.9, -1.6)</p></td></tr><tr><td style="vertical-align:top"><p>(LS mean&dagger;, 95% CI)</p></td></tr></tbody></table><p>*&nbsp;&nbsp; &nbsp;N includes all randomised, treated patients who had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Least squares means adjusted for treatment, time, baseline eGFR and the interaction of time by treatment.</p><p>&Dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p&lt; 0.001 compared to control group.</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p&lt; 0.001 compared to corresponding dose of ertugliflozin or sitagliptin (based on adjusted odds ratio comparisons from a logistic regression model using multiple imputation for missing data values).</p><p>&nbsp;</p><p><em>Ertugliflozin as add-on combination</em><em> </em><em>therapy with </em><em>metformin</em><em> and </em><em>sitagliptin</em></p><p>A total of 463 patients with type 2 diabetes inadequately controlled on metformin (&ge; 1,500 mg/day) and sitagliptin 100 mg once daily participated in a randomised, double-blind, multi-centre, 26-week, placebo-controlled study to evaluate the efficacy and safety of ertugliflozin. Patients were randomised to ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo administered once daily in addition to continuation of background metformin and sitagliptin therapy (see Table 4).</p><p>&nbsp;</p><p>Table 4: Results at Week 26 from an add-on study of ertugliflozin in combination with metformin and sitagliptin*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Ertugliflozin </strong><strong>5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Ertugliflozin 15</strong><strong> </strong><strong>mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 156</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>8.0</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-0.8</p></td><td style="vertical-align:top"><p>-0.9</p></td><td rowspan="2" style="vertical-align:top"><p>-0.1</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-0.7&Dagger; (-0.9, -0.5)</p></td><td style="vertical-align:top"><p>-0.8&Dagger; (-0.9, -0.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients [N (%)] with HbA1c &lt; 7%</strong></p></td><td style="vertical-align:top"><p>50 (32.1)&sect;</p></td><td style="vertical-align:top"><p>61 (39.9)&sect;</p></td><td style="vertical-align:top"><p>26 (17.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 156</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>87.6</p></td><td style="vertical-align:top"><p>86.6</p></td><td style="vertical-align:top"><p>86.5</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-3.3</p></td><td style="vertical-align:top"><p>-3.0</p></td><td rowspan="2" style="vertical-align:top"><p>-1.3</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-2.0&Dagger; (-2.6, -1.4)</p></td><td style="vertical-align:top"><p>-1.7&Dagger; (-2.3, -1.1)</p></td></tr></tbody></table><p>*&nbsp; N includes all randomised, treated patients who had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp;&nbsp;&nbsp; Least squares means adjusted for treatment, time, prior antihyperglycaemic medication, baseline eGFR, and the interaction of time by treatment.</p><p>&Dagger;&nbsp;&nbsp;&nbsp; p&pound; 0.001 compared to placebo.</p><p>&sect;&nbsp;&nbsp;&nbsp; p&lt; 0.001 compared to placebo (based on adjusted odds ratio comparisons from a logistic regression model using multiple imputation for missing data values).</p><p>&nbsp;</p><p><em>Active-controlled study</em><em> of ertugliflozin versus glimepiride as add-on combination therapy with metformin</em></p><p>A total of 1,326 patients with type 2 diabetes inadequately controlled on metformin monotherapy participated in a randomised, double-blind, multi-centre, 52-week, active comparator-controlled study to evaluate the efficacy and safety of ertugliflozin in combination with metformin. These patients, who were receiving metformin monotherapy (&ge; 1,500 mg/day), were randomised to ertugliflozin 5 mg, ertugliflozin 15 mg, or glimepiride administered once daily in addition to continuation of background metformin therapy. Glimepiride was initiated at 1 mg/day and titrated up to a maximum dose of 6 or</p><p>8 mg/day (depending on maximum approved dose in each country) or a maximum tolerated dose or down-titrated to avoid or manage hypoglycaemia. The mean daily dose of glimepiride was 3.0 mg (see Table 5).</p><p>&nbsp;</p><p>Table 5: Results at Week 52 from an active-controlled study comparing ertugliflozin to glimepiride as add-on therapy in patients inadequately controlled on metformin*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Ertugliflozin </strong><strong>5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Ertugliflozin 15</strong><strong> </strong><strong>mg</strong></p></td><td style="vertical-align:top"><p><strong>Glimepiride</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 448</strong></p></td><td style="vertical-align:top"><p><strong>N = 440</strong></p></td><td style="vertical-align:top"><p><strong>N = 437</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>7.8</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-0.6</p></td><td style="vertical-align:top"><p>-0.6</p></td><td rowspan="2" style="vertical-align:top"><p>-0.7</p></td></tr><tr><td style="vertical-align:top"><p>Difference from glimepiride (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>0.2 (0.1, 0.3)</p></td><td style="vertical-align:top"><p>0.1&Dagger; (-0.0, 0.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients [N (%)] with HbA1c &lt; 7%</strong></p></td><td style="vertical-align:top"><p>154 (34.4)</p></td><td style="vertical-align:top"><p>167 (38.0)</p></td><td style="vertical-align:top"><p>190 (43.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 448</strong></p></td><td style="vertical-align:top"><p><strong>N = 440</strong></p></td><td style="vertical-align:top"><p><strong>N = 437</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>87.9</p></td><td style="vertical-align:top"><p>85.6</p></td><td style="vertical-align:top"><p>86.8</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-3.0</p></td><td style="vertical-align:top"><p>-3.4</p></td><td rowspan="2" style="vertical-align:top"><p>0.9</p></td></tr><tr><td style="vertical-align:top"><p>Difference from glimepiride (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-3.9 (-4.4, -3.4)</p></td><td style="vertical-align:top"><p>-4.3&sect; (-4.8, -3.8)</p></td></tr></tbody></table><p>*&nbsp; N includes all randomised, treated patients who had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp;&nbsp;&nbsp; Least squares means adjusted for treatment, time, prior antihyperglycemic medication, baseline eGFR&nbsp; and the interaction of time by treatment.</p><p>&Dagger;&nbsp; &nbsp;Non-inferiority is declared when the upper bound of the two-sided 95% confidence interval (CI) for the mean difference is less than 0.3%.</p><p>&sect;&nbsp;&nbsp;&nbsp; p&lt; 0.001 compared to glimepiride.</p><p>&nbsp;</p><p><em>Fasting plasma glucose</em></p><p>In three placebo-controlled studies, ertugliflozin resulted in statistically significant reductions in FPG. For ertugliflozin 5 mg and 15 mg, respectively, the placebo-corrected reductions in FPG were 1.92 and</p><p>2.44 mmol/l as monotherapy, 1.48 and 2.12 mmol/l as add-on to metformin, and 1.40 and 1.74 mmol/l as add-on to metformin and sitagliptin.</p><p>&nbsp;</p><p>The combination of ertugliflozin and sitagliptin on a background of metformin resulted in significantly greater reductions in FPG compared to sitagliptin or ertugliflozin alone. The combination of ertugliflozin 5 or 15 mg and sitagliptin resulted in incremental FPG reductions of 0.46 and</p><p>0.65 mmol/l compared to the ertugliflozin alone or 1.02 and 1.28 mmol/l compared to sitagliptin alone, respectively.</p><p>&nbsp;</p><p><em>Efficacy in patients with baseline HbA1c</em><em> </em><em>&ge; 9%</em></p><p>In the study of ertugliflozin in combination with metformin in patients with baseline HbA1c from 7.0-10.5%, the placebo-corrected reductions in HbA1c for the subgroup of patients in the study with baseline HbA1c &ge; 9% were 1.31% and 1.43% with ertugliflozin 5 mg and 15 mg, respectively.</p><p>&nbsp;</p><p>In the study of patients inadequately controlled on metformin with baseline HbA1c from 7.5-11.0%, among the subgroup of patients with a baseline HbA1c &ge; 10%, the combination of ertugliflozin 5 mg &nbsp;or 15 mg with sitagliptin resulted in reductions of HbA1c of 2.35% and 2.66%, respectively, compared to 2.10%, 1.30%, and 1.82% for ertugliflozin 5 mg, ertugliflozin 15 mg, and sitagliptin alone, respectively.</p><p>&nbsp;</p><p><em>Blood pressure</em></p><p>As add-on to metformin, ertugliflozin 5 mg and 15 mg resulted in statistically significant placebo-corrected reductions in SBP of 3.7 mmHg and 4.5 mmHg, respectively. As add-on to metformin and sitagliptin, ertugliflozin 5 mg and 15 mg resulted in statistically significant placebo-corrected reductions in SBP of 2.9 mmHg and 3.9 mmHg, respectively.</p><p>&nbsp;</p><p>In a 52-week, active-controlled study versus glimepiride, reductions from baseline in SBP were</p><p>2.2 mmHg and 3.8 mmHg for ertugliflozin 5 mg and 15 mg, respectively, while subjects treated with glimepiride had an increase in SBP from baseline of 1.0 mmHg.</p><p>&nbsp;</p><p><em>Subgroup analysis</em></p><p>In patients with type 2 diabetes treated with ertugliflozin in combination with metformin, clinically meaningful reductions in HbA1c were observed in subgroups defined by age, sex, race, ethnicity, geographic region, baseline BMI, baseline HbA1c, and duration of type 2 diabetes mellitus.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Segluromet in all subsets of the paediatric population in the treatment of type 2 diabetes (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Segluromet</u></p><p>Segluromet has been shown to be bioequivalent to coadministration of corresponding doses of ertugliflozin and metformin tablets.</p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>&nbsp;</p><p><em><u>General introduction</u></em></p><p>The pharmacokinetics of ertugliflozin are similar in healthy subjects and patients with type 2 diabetes. The steady state mean plasma AUC and Cmax were 398 ng∙hr/ml and 81 ng/ml, respectively, with 5 mg ertugliflozin once daily treatment, and 1,193 ng∙hr/ml and 268 ng/ml, respectively, with 15 mg ertugliflozin once daily treatment. Steady-state is reached after 4 to 6 days of once-daily dosing with ertugliflozin. Ertugliflozin does not exhibit time-dependent pharmacokinetics and accumulates in plasma up to 10-40% following multiple dosing.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Following single-dose oral administration of 5 mg and 15 mg of ertugliflozin, peak plasma concentrations (median Tmax) of ertugliflozin occur at 1 hour post-dose under fasted conditions. Plasma Cmax&nbsp;and AUC of ertugliflozin increase in a dose-proportional manner following single doses from 0.5 mg to 300 mg and following multiple doses from 1 mg to 100 mg. The absolute oral bioavailability of ertugliflozin following administration of a 15-mg dose is approximately 100%.</p><p>&nbsp;</p><p>Administration of ertugliflozin with a high-fat and high-calorie meal decreases ertugliflozin Cmax&nbsp;by 29% and prolongs Tmax&nbsp;by 1 hour, but does not alter AUC as compared with the fasted state. The observed effect of food on ertugliflozin pharmacokinetics is not considered clinically relevant, and ertugliflozin may be administered with or without food. In Phase 3 clinical trials, ertugliflozin was administered without regard to meals.</p><p>&nbsp;</p><p>The effects of a high-fat meal on the pharmacokinetics of ertugliflozin and metformin when administered as Segluromet tablets are comparable to those reported for the individual tablets. Food had no meaningful effect on AUCinf&nbsp;of ertugliflozin or metformin, but reduced mean ertugliflozin Cmax&nbsp;by approximately 41% and metformin Cmax&nbsp;by approximately 29% compared to the fasted condition.</p><p>&nbsp;</p><p>Ertugliflozin is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The mean steady-state volume of distribution of ertugliflozin following an intravenous dose is 86 l. Plasma protein binding of ertugliflozin is 93.6% and is independent of ertugliflozin plasma concentrations. Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment. The blood-to-plasma concentration ratio of ertugliflozin is 0.66.</p><p>&nbsp;</p><p>Ertugliflozin is not a substrate of organic anion transporters (OAT1, OAT3), organic cation transporters (OCT1, OCT2), or organic anion transporting polypeptides (OATP1B1, OATP1B3) <em>in vitro.</em></p><p><em>&nbsp;</em></p><p><u>Biotransformation</u></p><p>Metabolism is the primary clearance mechanism for ertugliflozin. The major metabolic pathway for ertugliflozin is UGT1A9 and UGT2B7-mediated O-glucuronidation to two glucuronides that are pharmacologically inactive at clinically relevant concentrations. CYP-mediated (oxidative) metabolism of ertugliflozin is minimal (12%).</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The mean systemic plasma clearance following an intravenous 100 &micro;g dose was 11 l/hr. The mean elimination half-life in type 2 diabetic patients with normal renal function was estimated to be</p><p>17 hours based on the population pharmacokinetic analysis. Following administration of an oral [14C]-ertugliflozin solution to healthy subjects, approximately 41% and 50% of the drug-related</p><p>radioactivity was eliminated in faeces and urine, respectively. Only 1.5% of the administered dose was excreted as unchanged ertugliflozin in urine and 34% as unchanged ertugliflozin in faeces, which is likely due to biliary excretion of glucuronide metabolites and subsequent hydrolysis to parent.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In a Phase 1 clinical pharmacology study in patients with type 2 diabetes and mild, moderate, or severe renal impairment (as determined by eGFR), following a single-dose administration of 15 mg ertugliflozin, the mean increases in AUC of ertugliflozin were &le; 1.7-fold, compared to subjects with normal renal function. These increases in ertugliflozin AUC are not considered clinically relevant.</p><p>There were no clinically meaningful differences in the ertugliflozin Cmax&nbsp;values among the different renal function groups. The 24-hour urinary glucose excretion declined with increasing severity of renal impairment (see section 4.4). The plasma protein binding of ertugliflozin was unaffected in patients with renal impairment.</p><p>&nbsp;</p><p><em>Hepatic</em><em> impairment</em></p><p>Moderate hepatic impairment (based on the Child-Pugh classification) did not result in an increase in exposure of ertugliflozin. The AUC of ertugliflozin decreased by approximately 13%, and Cmax&nbsp;decreased by approximately 21% compared to subjects with normal hepatic function. This decrease in ertugliflozin exposure is not considered clinically meaningful. There is no clinical experience in patients with Child-Pugh class C (severe) hepatic impairment. The plasma protein binding of ertugliflozin was unaffected in patients with moderate hepatic impairment.</p><p>&nbsp;</p><p><em>Paediatric</em><em> population</em></p><p>No studies with ertugliflozin have been performed in paediatric patients.</p><p>&nbsp;</p><p><em>Effects of age, body weight, gender and race</em></p><p>Based on a population pharmacokinetic analysis, age, body weight, gender, and race do not have a clinically meaningful effect on the pharmacokinetics of ertugliflozin.</p><p>&nbsp;</p><p><u>Drug Interactions</u></p><p>&nbsp;</p><p>In vitro <em>assessment of ertugliflozin</em></p><p>In <em>in vitro </em>studies, ertugliflozin and ertugliflozin glucuronides did not inhibit or inactivate CYPs 1A2, 2C9, 2C19, 2C8, 2B6, 2D6, or 3A4, and did not induce CYPs 1A2, 2B6, or 3A4. Ertugliflozin and ertugliflozin glucuronides did not inhibit the activity of UGTs 1A6, 1A9 or 2B7 <em>in vitro</em>. Ertugliflozin was a weak inhibitor of UGTs 1A1 and 1A4 <em>in</em><em> vitro </em>at higher concentrations that are not clinically relevant. Ertugliflozin glucuronides had no effect on these isoforms. Overall, ertugliflozin is unlikely to affect the pharmacokinetics of concurrently administered drugs eliminated by these enzymes.</p><p>&nbsp;</p><p>Ertugliflozin or ertugliflozin glucuronides do not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 transporters or transporting polypeptides OATP1B1 and OATP1B3 at clinically relevant concentrations <em>in vitro</em>. Overall, ertugliflozin is unlikely to affect the pharmacokinetics of concurrently administered medications that are substrates of these transporters.</p><p>&nbsp;</p><p><u>Metformin</u></p><p>&nbsp;</p><p><u>Absorption</u></p><p>The absolute bioavailability of a metformin hydrochloride 500-mg tablet given under fasting conditions is approximately 50-60%. Studies using single oral doses of metformin hydrochloride tablets 500 mg to 1,500 mg, and 850 mg to 2,550 mg, indicate that there is a lack of dose proportionality with increasing doses, which is due to decreased absorption rather than an alteration in elimination. At usual clinical doses and dosing schedules of metformin hydrochloride tablets, steady- state plasma concentrations of metformin are reached within 24-48 hours and are generally &lt;1 &micro;g/ml. During controlled clinical trials of metformin, maximum metformin plasma levels did not exceed</p><p>5 &micro;g/mL, even at maximum doses.</p><p>&nbsp;</p><p>Food decreases the extent of and slightly delays the absorption of metformin, as shown by approximately a 40% lower mean peak plasma concentration (Cmax), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak plasma concentration (Tmax) following administration of a single 850-mg tablet of metformin with food, compared to the same tablet strength administered fasting. The clinical relevance of these decreases is unknown.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The apparent volume of distribution (V/F) of metformin following single oral doses of metformin hydrochloride tablets 850 mg averaged 654 &plusmn; 358 l. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Metformin is excreted unchanged in the urine. No metabolites have been identified in humans.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Renal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In patients with decreased renal function, the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased in proportion to the decrease in eGFR (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em>Hepatic</em><em> impairment</em></p><p>No pharmacokinetic studies of metformin have been conducted in patients with hepatic insufficiency.</p><p>&nbsp;</p><p><em>Effects of age, body weight, gender and race</em></p><p>Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and Cmax&nbsp;is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function.</p><p>&nbsp;</p><p>Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes when analysed according to gender. Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycaemic effect of metformin was comparable in males and females.</p><p>&nbsp;</p><p>No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type 2 diabetes, the antihyperglycaemic effect was comparable in Whites (n=249), Blacks (n=51), and Hispanics (n=24).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, acute toxicity, repeated dose toxicity, genotoxicity, and carcinogenic potential.</p><p>&nbsp;</p><p><u>General toxicity</u></p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>Repeat-dose oral toxicity studies were conducted in mice, rats, and dogs for up to 13, 26, and</p><p>39&nbsp; weeks, respectively. Signs of toxicity that were considered adverse were generally observed at exposures greater than or equal to 77 times the human unbound exposure (AUC) at the maximum recommended human dose (MRHD) of 15 mg/day. Most toxicity was consistent with pharmacology related to urinary glucose loss and included decreased body weight and body fat, increased food consumption, diarrhoea, dehydration, decreased serum glucose and increases in other serum parameters reflective of increased protein metabolism, gluconeogenesis and electrolyte imbalances, and urinary changes such as polyuria, glucosuria, and calciuria. Microscopic changes related to glucosuria and/or calciuria observed only in rodents included dilatation of renal tubules, hypertrophy of zona glomerulosa in adrenal glands (rats), and increased trabecular bone (rats). Except for emesis, there were no adverse toxicity findings in dogs at 379 times the human unbound exposure (AUC) at the MRHD of 15 mg/day.</p><p>&nbsp;</p><p><u>Carcinogenesis</u></p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>In the 2-year mouse carcinogenicity study, ertugliflozin was administered by oral gavage at doses of 5, 15, and 40 mg/kg/day. There were no ertugliflozin-related neoplastic findings at doses up to</p><p>40&nbsp; mg/kg/day (approximately 41 times human unbound exposure at the MRHD of 15 mg/day based on AUC). In the 2-year rat carcinogenicity study, ertugliflozin was administered by oral gavage at doses &nbsp;of 1.5, 5, and 15 mg/kg/day. Ertugliflozin-related neoplastic findings included an increased incidence of benign adrenal medullary pheochromocytoma in male rats at 15 mg/kg/day. This finding was attributed to carbohydrate malabsorption leading to altered calcium homeostasis and was not considered relevant to human risk. The no-observed-effect level (NOEL) for neoplasia was</p><p>5 mg/kg/day (approximately 16 times human unbound exposure at the MRHD of 15 mg/day).</p><p>&nbsp;</p><p><u>Metformin</u></p><p>Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1,500 mg/kg/day, respectively. These doses are both approximately four times the maximum recommended human daily dose of 2,000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day.</p><p>&nbsp;</p><p><u>Mutagenesis</u></p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>Ertugliflozin was not mutagenic or clastogenic with or without metabolic activation in the microbial reverse mutation, <em>in vitro </em>cytogenetic (human lymphocytes), and <em>in vivo </em>rat micronucleus assays.</p><p>&nbsp;</p><p><u>Metformin</u></p><p>There was no evidence of a mutagenic potential of metformin in the following <em>in vitro </em>tests: Ames test (<em>S. </em><em>typhimurium</em>), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the <em>in vivo </em>mouse micronucleus test were also negative.</p><p>&nbsp;</p><p><u>Reproductive toxicology</u></p><p>&nbsp;</p><p><u>Ertugliflozin</u></p><p>In the rat fertility and embryonic development study, male and female rats were administered ertugliflozin at 5, 25, and 250 mg/kg/day. No effects on fertility were observed at 250 mg/kg/day (approximately 386 times human unbound exposure at the MRHD of 15 mg/day based on AUC comparisons). Ertugliflozin did not adversely affect developmental outcomes in rats and rabbits at maternal exposures that were 239 and 1,069 times, respectively, the human exposure at the maximum clinical dose of 15 mg/day, based on AUC. At a maternally toxic dose in rats (250 mg/kg/day), lower foetal viability and a higher incidence of a visceral malformation were observed at maternal exposure that was 510 times the maximum clinical dose of 15 mg/day.</p><p>&nbsp;</p><p>In the pre- and post-natal development study, decreased post-natal growth and development were observed in rats administered ertugliflozin gestation day 6 through lactation day 21 at</p><p>&ge; 100 mg/kg/day (estimated 239 times the human exposure at the maximum clinical dose of</p><p>15 mg/day, based on AUC). Sexual maturation was delayed in both sexes at 250 mg/kg/day (estimated 620 times the MRHD at 15 mg/day, based on AUC).</p><p>&nbsp;</p><p>When ertugliflozin was administered to juvenile rats from post-natal day (PND) 21 to PND 90, a</p><p>period of renal development corresponding to the late second and third trimesters of human pregnancy, increased kidney weights, dilatation of the renal pelvis and tubules, and renal tubular mineralization were seen at an exposure 13 times the maximum clinical dose of 15 mg/day, based on AUC. Effects</p><p>on bone (shorter femur length, increased trabecular bone in the femur) as well as effects of delayed puberty were observed at an exposure 817 times the MHRD of 15 mg/day based on AUC. The effects on kidney and bone did not fully reverse after the 1-month recovery period.</p><p>&nbsp;</p><p><u>Metformin</u></p><p><!--[if gte vml 1]><v:group
 id="Group_x0020_2" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:251.3pt;margin-top:36.8pt;width:2.8pt;height:.5pt;
 z-index:-36256;mso-position-horizontal-relative:page' coordorigin="5026,736"
 coordsize="56,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
">
 <v:shape id="Freeform_x0020_3" o:spid="_x0000_s1027" style='position:absolute;
  left:5026;top:736;width:56;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="56,10" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD903qGwAAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Bi8Iw
FITvgv8hPGEvsqYqLNI1iiiCR62CHp/J27Zs81KSqN1/bwRhj8PMfMPMl51txJ18qB0rGI8yEMTa
mZpLBafj9nMGIkRkg41jUvBHAZaLfm+OuXEPPtC9iKVIEA45KqhibHMpg67IYhi5ljh5P85bjEn6
UhqPjwS3jZxk2Ze0WHNaqLCldUX6t7hZBSbqvdfXzXFy2her4eVwvtbISn0MutU3iEhd/A+/2zuj
YAqvK+kGyMUTAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAAAAAA
AAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAAAAAA
AAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA/dN6hsAAAADaAAAADwAAAAAA
AAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPQCAAAAAA==
" path="m,5r55,e" filled="f" strokeweight=".58pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,741;55,741"
   o:connectangles="0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="6" height="2" src="file:///C:/Users/alsirhan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately three times the maximum recommended human daily dose based on body surface area comparisons. Metformin did not adversely affect developmental outcomes when administered to rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 6 times the exposure at the maximum recommended human dose of 2,000 mg based on body surface area comparisons for rats and rabbits, respectively. Determination of foetal concentrations demonstrated a partial placental barrier to metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Tablet core</u></p><p>Povidone K29-32 (E1201) Microcrystalline cellulose (E460) Crospovidone (E1202)</p><p>Sodium lauryl sulfate (E487) Magnesium stearate (E470b)</p><p>&nbsp;</p><p><u>Film coating</u></p><p>&nbsp;</p><p><em><u>Segluromet 2.5 mg/1,000</u></em><em><u> mg film-coated tablets and Segluromet 7.5 mg/1,000 mg film-coated tablets</u></em></p><p>Hypromellose (E464) Hydroxypropyl cellulose (E463) Titanium dioxide (E171)</p><p>Iron oxide red (E172) Carnauba wax (E903)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.&nbsp; Store in the original package</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu/PVC/PA/Alu blisters.</p><p>Packs of 14, 28, 56, 60, 168, and 180 film-coated tablets in non-perforated blisters and multipacks containing 196 (4 packs of 49) film-coated tablets in non-perforated blisters.</p><p>Packs of 30x1 film-coated tablets in perforated unit dose blisters. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder:
Merck Sharp & Dohme B.V.
Waarderweg 
2031 BN Haarlem 
The Netherlands

Manufacturer:
MSD International GmbH (Puerto Rico Branch) L.L.C.
State Road 183
PRIDCO Industrial Park
Las Piedras, Puerto Rico 00771 United States

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2020

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>